Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Michael Birrer

TitleCancer Institute Director
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentCollege of Cancer Institute
Address4104 Outpatient Circle
Mail Slot # 508
Little Rock AR 72205
vCardDownload vCard
    Other Positions
    TitleProfessor
    InstitutionUniversity of Arkansas for Medical Sciences
    DepartmentInternal Medicine, College of Medicine
    DivisionHematology Oncology


    Collapse Research 
    Collapse research activities and funding
    CE1HS53555     (BIRRER, MICHAEL)Sep 30, 2024 - Sep 29, 2027
    Health Resources & Services Administration
    Cancer Care Mobile Vans, Computerized Tomography Equipment, and Lung Cancer Screening
    Role: Principal Investigator
    U01CA294459     (MOK, SAMUEL C)Sep 1, 2024 - Aug 31, 2029
    NIH
    3D Spatial Multi-Omics Profiling of Ovarian Cancer
    Role: Co-Principal Investigator
    CE1HS52094     (BIRRER, MICHAEL)Sep 30, 2023 - Sep 29, 2026
    Health Resources & Services Administration
    Community Project Funding/Congressionally Directed Spending - Construction
    Role: Principal Investigator
    CE1HS52245     (BIRRER, MICHAEL)Sep 30, 2023 - Sep 29, 2026
    Health Resources & Services Administration
    Regional Cancer Care Facilities and Equipment
    Role: Principal Investigator
    CE1HS52481     (BIRRER, MICHAEL)Sep 30, 2023 - Sep 29, 2026
    Health Resources & Services Administration
    Cancer Care Mobile Van and Mammography Equipment
    Role: Principal Investigator
    BLU     (BIRRER, MICHAEL)Oct 24, 2022 - Oct 23, 2023
    Blueprint Medicines Corporation
    A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
    Role: Principal Investigator
    BLU-222-1101     (BIRRER, MICHAEL)Oct 24, 2022 - Oct 23, 2023
    Blueprint Medicines Corporation
    A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
    Role: Principal Investigator
    CTF     (BIRRER, MICHAEL)Jul 1, 2022 - Jun 30, 2024
    Children's Tumor Foundation
    Adult NF Clinic Program Building Pilot Project
    Role: Principal Investigator
    UAMS C24914     (BIRRER, MICHAEL)May 13, 2022 - May 12, 2023
    Artios Pharma Limited
    A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy...
    Role: Principal Investigator
    UAMSC24914     (BIRRER, MICHAEL)May 13, 2022 - May 12, 2023
    Artios Pharma Limited
    A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy...
    Role: Principal Investigator
    NP-G2     (BIRRER, MICHAEL)Feb 24, 2022 - Feb 23, 2023
    Novita Pharmaceuticals, Inc. - Pass Through: Medpace Clinical Research
    NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
    Role: Principal Investigator
    NP-G2-044-P2-01     (BIRRER, MICHAEL)Feb 24, 2022 - Feb 23, 2023
    Novita Pharmaceuticals, Inc. - Pass Through: Medpace Clinical Research
    NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
    Role: Principal Investigator
    U01CA152990     (WILLIAMS, HEATHER R)Apr 1, 2021 - Mar 31, 2025
    NIH/Nat. Cancer Institute - Pass Through: Massachusetts General Hospital
    OVARIAN CANCER DETECTION BY UTERINE LAVAGE DNA AND SERUM PROTEINS: A PHASE 2 BIOMARKER STUDY
    Role: Co-Principal Investigator
    227914     (BIRRER, MICHAEL)Apr 1, 2021 - Mar 31, 2022
    NIH/Nat. Cancer Institute - Pass Through: Massachusetts General Hospital
    Proteomic, Genomic, + Longitudinal Pathways to Ovarian Cancer Biomarker Discovery
    Role: Principal Investigator
    W81XWH-16-2-0038-P00003     (BIRRER, MICHAEL)Mar 15, 2021 - Dec 25, 2023
    US Department of Defense
    The Genomic, Epigenomic, and Quality-of-Life Characteristics of Long-Term Survivors of Ovarian Cancer
    Role: Principal Investigator
    W81XWH-16-2-0038     (BIRRER MICHAEL)Mar 15, 2021 - Dec 25, 2022
    Department of Defense
    The Genomic, Epigenomic, and Quality-of-Life Characteristics of Long-Term Survivors of Ovarian Cancer
    Role: Principal Investigator
    U10CA180868     (BIRRER, MICHAEL)Mar 1, 2021 - Feb 28, 2025
    NIH/Nat. Cancer Institute - Pass Through: NRG Oncology Foundation
    NRG Oncology Network Group Operation Center
    Role: Principal Investigator
    W81XWH-17-1-0225     (BIRRER, MICHAEL)Dec 15, 2020 - Dec 14, 2023
    US Department of Defense
    Treatment of Recurrent, Platinum-Resistant Ovarian Cancer with Glutaminase 1 and PARP Inhibitors
    Role: Principal Investigator
    MS200647     (BIRRER, MICHAEL)Sep 29, 2020 - Sep 28, 2021
    EMD Serono Research & Development Institute - Pass Through: IQVIA, Inc.
    A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Containing Chemotherapy
    Role: Principal Investigator
    MS200647-0017     (BIRRER, MICHAEL)Sep 29, 2020 - Sep 28, 2021
    EMD Serono Research & Development Institute - Pass Through: IQVIA, Inc.
    A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Containing Chemotherapy
    Role: Principal Investigator
    R01CA218973     (BIRRER, MICHAEL)Aug 13, 2020 - Apr 30, 2021
    NIH/Nat. Cancer Institute
    Validation of a genomic signature that predicts for sub-optimal debulking of epithelial ovarian cancer
    Role: Principal Investigator
    W81XWH-18-1-0157     (BIRRER, MICHAEL)May 15, 2018 - May 14, 2022
    US Department of Defense
    Overcoming PARP Inhibitor Resistance of BRCA-Deficient Ovarian Cancers
    Role: Principal Investigator
    R21CA218973     (BIRRER, MICHAEL)May 1, 2018 - Apr 30, 2021
    NIH
    Validation of a genomic signature that predicts for sub-optimal debulking of epithelial ovarian cancer
    Role: Principal Investigator
    U01CA214114     (PAULOVICH, AMANDA G)Jun 1, 2017 - May 31, 2022
    NIH
    Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit
    Role: Co-Principal Investigator
    R01CA169200     (BIRRER, MICHAEL)Mar 1, 2013 - Feb 28, 2019
    NIH
    The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer
    Role: Principal Investigator
    RC4CA156551     (BIRRER, MICHAEL)Sep 27, 2010 - Aug 31, 2013
    NIH
    Genomic Stratification of Ovarian Cancer Patients
    Role: Principal Investigator
    R01CA142832     (BIRRER, MICHAEL)Mar 22, 2010 - Jan 31, 2016
    NIH
    Novel Biomarkers in Ovarian Cancer
    Role: Principal Investigator
    W81XWH     (WARE, JERRY)Sep 1, 2008 - Aug 31, 2011
    US Department of the Army
    Platelet glycoprotein Ib-IX and malignancy
    Role: Principal Investigator
    U54CA118948     (MANNE, UPENDER)Sep 23, 2005 - Aug 31, 2026
    NIH
    3/3 Morehouse School of Medicine/Tuskegee University/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership
    Role: Co-Principal Investigator
    P30CA013148     (SLECKMAN, BARRY P)Feb 1, 1978 - Aug 31, 2027
    NIH
    Comprehensive Cancer Center Support Grant
    Role: Co-Principal Investigator
    ZIASC000165     (BIRRER, MICHAEL)
    NIH
    The Use of Transcriptional Factors as Targets and Agents in Carcinogenesis
    Role: Principal Investigator
    ZIASC000181     (BIRRER, MICHAEL)
    NIH
    The Molecular Genetics of Gynecologic Cancers
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions. Don't see publications published under other names? Login to add alternative names.
    List All   |   Timeline
    1. Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O'Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P, Method M, Wang Y, Coleman RL, Birrer M, Matulonis UA. Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary. Gynecol Oncol. 2024 Oct 25; 191:249-258. PMID: 39461270.
      View in: PubMed
    2. Birrer M, Li G, Yunokawa M, Lee JY, Kim BG, Oppermann CP, Zhou Q, Nishio S, Okamoto A, Wu X, Mileshkin L, Oaknin A, Ray-Coquard I, Hasegawa K, Jehl G, Vugmeyster Y, Zhang S, Bajars M, Yonemori K. Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Sep 01; 10(9):1204-1211. PMID: 39052242.
      View in: PubMed
    3. Zhang Z, Huang L, Brayboy L, Birrer M. Single-cell analysis of ovarian myeloid cells identifies aging associated changes in macrophages and signaling dynamics. bioRxiv. 2024 Jun 16. PMID: 38915572.
      View in: PubMed
    4. Andrews JT, Zhang Z, Prasad GVRK, Huey F, Nazarova EV, Wang J, Ranaraja A, Weinkopff T, Li LX, Mu S, Birrer MJ, Huang SC, Zhang N, Arg?ello RJ, Philips JA, Mattila JT, Huang L. Metabolically active neutrophils represent a permissive niche for Mycobacterium tuberculosis. Mucosal Immunol. 2024 Oct; 17(5):825-842. PMID: 38844208.
      View in: PubMed
    5. Scalise CB, Kincaid K, Thigpen H, Moore J, Dover B, Norian L, Meza-Perez S, Randall T, Birrer M, Odunsi K, Arend RC. A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment. Gynecol Oncol. 2024 06; 185:83-94. PMID: 38377762.
      View in: PubMed
    6. Ferri-Borgogno S, Burks JK, Seeley EH, McKee TD, Stolley DL, Basi AV, Gomez JA, Gamal BT, Ayyadhury S, Lawson BC, Yates MS, Birrer MJ, Lu KH, Mok SC. Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics Analyses. Cancers (Basel). 2024 Feb 20; 16(5). PMID: 38473208.
      View in: PubMed
    7. Chowdhury S, Kennedy JJ, Ivey RG, Murillo OD, Hosseini N, Song X, Petralia F, Calinawan A, Savage SR, Berry AB, Reva B, Ozbek U, Krek A, Ma W, da Veiga Leprevost F, Ji J, Yoo S, Lin C, Voytovich UJ, Huang Y, Lee SH, Bergan L, Lorentzen TD, Mesri M, Rodriguez H, Hoofnagle AN, Herbert ZT, Nesvizhskii AI, Zhang B, Whiteaker JR, Fenyo D, McKerrow W, Wang J, Sch?rer SC, Stathias V, Chen XS, Barcellos-Hoff MH, Starr TK, Winterhoff BJ, Nelson AC, Mok SC, Kaufmann SH, Drescher C, Cieslik M, Wang P, Birrer MJ, Paulovich AG. Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer. Cell. 2024 Feb 15; 187(4):1016. PMID: 38364782.
      View in: PubMed
    8. Ledermann JA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, Gonz?lez-Mart?n A, Oaknin A, Ottevanger PB, Rudaitis V, Kobie J, Nebozhyn M, Edmondson M, Sun Y, Cristescu R, Jelinic P, Keefe SM, Matulonis UA. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100. Gynecol Oncol. 2023 11; 178:119-129. PMID: 37862791.
      View in: PubMed
    9. Chowdhury S, Kennedy JJ, Ivey RG, Murillo OD, Hosseini N, Song X, Petralia F, Calinawan A, Savage SR, Berry AB, Reva B, Ozbek U, Krek A, Ma W, da Veiga Leprevost F, Ji J, Yoo S, Lin C, Voytovich UJ, Huang Y, Lee SH, Bergan L, Lorentzen TD, Mesri M, Rodriguez H, Hoofnagle AN, Herbert ZT, Nesvizhskii AI, Zhang B, Whiteaker JR, Fenyo D, McKerrow W, Wang J, Sch?rer SC, Stathias V, Chen XS, Barcellos-Hoff MH, Starr TK, Winterhoff BJ, Nelson AC, Mok SC, Kaufmann SH, Drescher C, Cieslik M, Wang P, Birrer MJ, Paulovich AG. Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer. Cell. 2023 08 03; 186(16):3476-3498.e35. PMID: 37541199.
      View in: PubMed
    10. LaFargue CJ, Amero P, Noh K, Mangala LS, Wen Y, Bayraktar E, Umamaheswaran S, Stur E, Dasari SK, Ivan C, Pradeep S, Yoo W, Lu C, Jennings NB, Vathipadiekal V, Hu W, Chelariu-Raicu A, Ku Z, Deng H, Xiong W, Choi HJ, Hu M, Kiyama T, Mao CA, Ali-Fehmi R, Birrer MJ, Liu J, Zhang N, Lopez-Berestein G, de Franciscis V, An Z, Sood AK. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. Nat Commun. 2023 04 26; 14(1):2407. PMID: 37100807.
      View in: PubMed
    11. Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, Bradley W, Sachdev J, Sirard CA, O'Malley DM, Birrer M. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. Gynecol Oncol. 2023 05; 172:82-91. PMID: 37001446.
      View in: PubMed
    12. Penson RT, Ambrosio AJ, Whalen CA, Krasner CN, Konstantinopoulos PA, Bradley C, Matulonis UA, Birrer MJ. Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer. Oncologist. 2023 03 17; 28(3):252-257. PMID: 36718018.
      View in: PubMed
    13. Osann K, Wenzel L, McKinney C, Wagner L, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Birrer M. Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors. Gynecol Oncol. 2023 04; 171:151-158. PMID: 36905875.
      View in: PubMed
    14. Tewari KS, Sill MW, Birrer MJ, Penson RT, Huang H, Moore DH, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study. Gynecol Oncol. 2023 04; 171:141-150. PMID: 36898292.
      View in: PubMed
    15. Sato S, Gillette M, de Santiago PR, Kuhn E, Burgess M, Doucette K, Feng Y, Mendez-Dorantes C, Ippoliti PJ, Hobday S, Mitchell MA, Doberstein K, Gysler SM, Hirsch MS, Schwartz L, Birrer MJ, Skates SJ, Burns KH, Carr SA, Drapkin R. LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. Sci Rep. 2023 01 27; 13(1):1537. PMID: 36707610.
      View in: PubMed
    16. Banerjee S, Drapkin R, Richardson DL, Birrer M. Targeting NaPi2b in ovarian cancer. Cancer Treat Rev. 2023 Jan; 112:102489. PMID: 36446254.
      View in: PubMed
    17. Campos S, Matulonis U, Berlin S, Horowitz N, Liu J, Krasner C, Hang L, Zarwan C, Barry W, Colella T, Whalen C, Shoni M, Lundquist C, Birrer MJ, Penson R. A randomized phase II trial of bevacizumab vs. bevacizumab and erlotinib as first-line consolidation after carboplatin, paclitaxel, and bevacizumab in newly diagnosed patients with mullerian tumors. Int J Clin Oncol. 2022 Dec; 27(12):1881-1890. PMID: 36344654.
      View in: PubMed
    18. Farley JH, Brady WE, O'Malley D, Fujiwara K, Yonemori K, Bonebrake A, Secord AA, Stephan JM, Walker JL, Nam JH, Birrer MJ, Gershenson DM. A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial. Gynecol Oncol. 2022 Dec; 167(3):423-428. PMID: 36244829.
      View in: PubMed
    19. Casablanca Y, Wang G, Lankes HA, Tian C, Bateman NW, Miller CR, Chappell NP, Havrilesky LJ, Wallace AH, Ramirez NC, Miller DS, Oliver J, Mitchell D, Litzi T, Blanton BE, Lowery WJ, Risinger JI, Hamilton CA, Phippen NT, Conrads TP, Mutch D, Moxley K, Lee RB, Backes F, Birrer MJ, Darcy KM, Maxwell GL. Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study. Cancers (Basel). 2022 Aug 23; 14(17). PMID: 36077609.
      View in: PubMed
    20. Chowdhury S, Wang R, Yu Q, Huntoon CJ, Karnitz LM, Kaufmann SH, Gygi SP, Birrer MJ, Paulovich AG, Peng J, Wang P. DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer. BMC Bioinformatics. 2022 Aug 05; 23(1):321. PMID: 35931981.
      View in: PubMed
    21. Birrer MJ, Fujiwara K, Oaknin A, Randall L, Ojalvo LS, Valencia C, Ray-Coquard I. The Changing Landscape of Systemic Treatment for Cervical Cancer: Rationale for Inhibition of the TGF-? and PD-L1 Pathways. Front Oncol. 2022; 12:814169. PMID: 35280818.
      View in: PubMed
    22. Grushko TA, Filiaci VL, Montag AG, Apushkin M, Gomez MJ, Monovich L, Ramirez NC, Schwab C, Kesterson JP, Seward SM, Method MW, Olopade OI, Fleming GF, Birrer MJ. Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. Appl Immunohistochem Mol Morphol. 2022 01 01; 30(1):27-35. PMID: 34224438.
      View in: PubMed
    23. Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, Whiteaker JR, Lin C, Hou X, Oberg AL, Larson MC, Eskandari N, Delisi DA, Gentile S, Huntoon CJ, Voytovich UJ, Shire ZJ, Yu Q, Gygi SP, Hoofnagle AN, Herbert ZT, Lorentzen TD, Calinawan A, Karnitz LM, Weroha SJ, Kaufmann SH, Zhang B, Wang P, Birrer MJ, Paulovich AG. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Rep Med. 2021 12 21; 2(12):100471. PMID: 35028612.
      View in: PubMed
    24. Swisher EM, Aghajanian C, O'Malley DM, Fleming GF, Kaufmann SH, Levine DA, Birrer MJ, Moore KN, Spirtos NM, Shahin MS, Reid TJ, Friedlander M, Steffensen KD, Okamoto A, Sehgal V, Ansell PJ, Dinh MH, Bookman MA, Coleman RL. Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253. PMID: 34906376.
      View in: PubMed
    25. Martinez A, Buckley MS, Scalise CB, Wang D, Katre AA, Birrer MJ, Berry JL, Arend RC. Utilization of a 3-D tissue engineered model to investigate the effects of perfusion on gynecologic cancer biology. J Tissue Eng. 2021 Jan-Dec; 12:20417314211055015. PMID: 34820113.
      View in: PubMed
    26. Bigelow EO, Harris J, Fakhry C, Gillison ML, Nguyen-T?n PF, Rosenthal DI, Frank SJ, Nair SG, Bahig H, Ridge JA, Caudell J, Donaldson C, Clifford BT, Shenouda G, Birrer MJ, Chen Y, Le QT. Risk stratification after recurrence of human papillomavirus (HPV)-related and non-HPV-related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522. Head Neck. 2022 01; 44(1):158-167. PMID: 34729846.
      View in: PubMed
    27. Huang D, Savage SR, Calinawan AP, Lin C, Zhang B, Wang P, Starr TK, Birrer MJ, Paulovich AG. A highly annotated database of genes associated with platinum resistance in cancer. Oncogene. 2021 11; 40(46):6395-6405. PMID: 34645978.
      View in: PubMed
    28. Wenzel L, Osann K, McKinney C, Cella D, Fulci G, Scroggins MJ, Lankes HA, Wang V, Nephew KP, Maxwell GL, Mok SC, Conrads TP, Miller A, Mannel RS, Gray HJ, Hanjani P, Huh WK, Spirtos N, Leitao MM, Glaser G, Sharma SK, Santin AD, Sperduto P, Lele SB, Burger RA, Monk BJ, Birrer M. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. J Natl Cancer Inst. 2021 10 01; 113(10):1369-1378. PMID: 33729494.
      View in: PubMed
    29. Monk BJ, Colombo N, Oza AM, Fujiwara K, Birrer MJ, Randall L, Poddubskaya EV, Scambia G, Shparyk YV, Lim MC, Bhoola SM, Sohn J, Yonemori K, Stewart RA, Zhang X, Perkins Smith J, Linn C, Ledermann JA. Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 09; 22(9):1275-1289. PMID: 34363762.
      View in: PubMed
    30. Krasner CN, Campos SM, Young CL, Chadda KR, Lee H, Birrer MJ, Horowitz NS, Konstantinopoulos PA, D'Ascanio AM, Matulonis UA, Penson RT. Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2021 09; 162(3):661-666. PMID: 34243976.
      View in: PubMed
    31. Martinez A, Buckley M, Scalise CB, Katre AA, Dholakia JJ, Crossman D, Birrer MJ, Berry JL, Arend RC. Understanding the effect of mechanical forces on ovarian cancer progression. Gynecol Oncol. 2021 07; 162(1):154-162. PMID: 33888338.
      View in: PubMed
    32. Zhu Y, Ferri-Borgogno S, Sheng J, Yeung TL, Burks JK, Cappello P, Jazaeri AA, Kim JH, Han GH, Birrer MJ, Mok SC, Wong STC. SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. Cancers (Basel). 2021 Apr 08; 13(8). PMID: 33917869.
      View in: PubMed
    33. Buechel ME, Enserro D, Burger RA, Brady MF, Wade K, Secord AA, Nixon AB, Mirniaharikandehei S, Liu H, Zheng B, O'Malley DM, Gray H, Tewari KS, Mannel RS, Birrer MJ, Moore KN. Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC). Gynecol Oncol. 2021 05; 161(2):382-388. PMID: 33712274.
      View in: PubMed
    34. Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary?analysis of FORWARD I. Ann Oncol. 2021 06; 32(6):757-765. PMID: 33667670.
      View in: PubMed
    35. Merritt MA, Strickler HD, Hutson AD, Einstein MH, Rohan TE, Xue X, Sherman ME, Brinton LA, Yu H, Miller DS, Ramirez NC, Lankes HA, Birrer MJ, Huang GS, Gunter MJ. Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer. Cancer Epidemiol Biomarkers Prev. 2021 04; 30(4):719-726. PMID: 33622671.
      View in: PubMed
    36. Chi RA, van der Watt P, Wei W, Birrer MJ, Leaner VD. Inhibition of Kpn?1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer. BMC Cancer. 2021 Feb 02; 21(1):106. PMID: 33530952.
      View in: PubMed
    37. Roane BM, Meza-Perez S, Katre AA, Goldsberry WN, Randall TD, Norian LA, Birrer MJ, Arend RC. Neutralization of TGF? Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma. Mol Cancer Ther. 2021 03; 20(3):602-611. PMID: 33323456.
      View in: PubMed
    38. Tewari KS, Sill MW, Monk BJ, Penson RT, Moore DH, Lankes HA, Ramondetta LM, Landrum LM, Randall LM, Oaknin A, Leitao MM, Eisenhauer EL, DiSilvestro P, Van Le L, Pearl ML, Burke JJ, Salani R, Richardson DL, Michael HE, Kindelberger DW, Birrer MJ. Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062). Mol Cancer Ther. 2020 11; 19(11):2363-2370. PMID: 32847980.
      View in: PubMed
    39. Betella I, Turbitt WJ, Szul T, Martinez A, Katre A, Wall JA, Norian L, Birrer MJ, Arend R. Corrigendum to 'Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer' [Gynecologic Oncology 157 (2020) 765-774]. Gynecol Oncol. 2020 Oct; 159(1):295. PMID: 32839025.
      View in: PubMed
    40. Da Silva DM, Enserro DM, Mayadev JS, Skeate JG, Matsuo K, Pham HQ, Lankes HA, Moxley KM, Ghamande SA, Lin YG, Schilder RJ, Birrer MJ, Kast WM. Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). Clin Cancer Res. 2020 11 01; 26(21):5621-5630. PMID: 32816895.
      View in: PubMed
    41. Geistlinger L, Oh S, Ramos M, Schiffer L, LaRue RS, Henzler CM, Munro SA, Daughters C, Nelson AC, Winterhoff BJ, Chang Z, Talukdar S, Shetty M, Mullany SA, Morgan M, Parmigiani G, Birrer MJ, Qin LX, Riester M, Starr TK, Waldron L. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma. Cancer Res. 2020 10 15; 80(20):4335-4345. PMID: 32747365.
      View in: PubMed
    42. Moore KN, Birrer MJ, Marsters J, Wang Y, Choi Y, Royer-Joo S, Lemahieu V, Armstrong K, Cordova J, Samineni D, Schuth E, Vaze A, Maslyar D, Humke EW, Hamilton EP, Liu JF. Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2020 09; 158(3):631-639. PMID: 32534811.
      View in: PubMed
    43. Santin AD, Filiaci V, Bellone S, O'Cearbhaill R, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Birrer MJ. Corrigendum to "Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG oncology study (NRG-GY008)" [Gynecol. Oncol. Rep. 31 (2020) 100532]. Gynecol Oncol Rep. 2020 Aug; 33:100590. PMID: 32885014.
      View in: PubMed
    44. Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2020 Apr 17; 11(1):1940. PMID: 32303677.
      View in: PubMed
    45. Doo DW, Meza-Perez S, Londo?o AI, Goldsberry WN, Katre AA, Boone JD, Moore DJ, Hudson CT, Betella I, McCaw TR, Gangrade A, Bao R, Luke JJ, Yang ES, Birrer MJ, Starenki D, Cooper SJ, Buchsbaum DJ, Norian LA, Randall TD, Arend RC. Inhibition of the Wnt/?-catenin pathway enhances antitumor immunity in ovarian cancer. Ther Adv Med Oncol. 2020; 12:1758835920913798. PMID: 32313567.
      View in: PubMed
    46. Arend RC, Beer HM, Cohen YC, Berlin S, Birrer MJ, Campos SM, Rachmilewitz Minei T, Harats D, Wall JA, Foxall ME, Penson RT. Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. Gynecol Oncol. 2020 06; 157(3):578-584. PMID: 32265057.
      View in: PubMed
    47. Goldsberry WN, Meza-Perez S, Londo?o AI, Katre AA, Mott BT, Roane BM, Goel N, Wall JA, Cooper SJ, Norian LA, Randall TD, Birrer MJ, Arend RC. Inhibiting WNT Ligand Production for Improved Immune Recognition in the Ovarian Tumor Microenvironment. Cancers (Basel). 2020 Mar 24; 12(3). PMID: 32213921.
      View in: PubMed
    48. Betella I, Turbitt WJ, Szul T, Wu B, Martinez A, Katre A, Wall JA, Norian L, Birrer MJ, Arend R. Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer. Gynecol Oncol. 2020 06; 157(3):765-774. PMID: 32192732.
      View in: PubMed
    49. O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020 05; 157(2):379-385. PMID: 32081463.
      View in: PubMed
    50. Alvarez Secord A, Bell Burdett K, Owzar K, Tritchler D, Sibley AB, Liu Y, Starr MD, Brady JC, Lankes HA, Hurwitz HI, Mannel RS, Tewari KS, O'Malley DM, Gray H, Bakkum-Gamez JN, Fujiwara K, Boente M, Deng W, Burger RA, Birrer MJ, Nixon AB. Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218. Clin Cancer Res. 2020 03 15; 26(6):1288-1296. PMID: 31919136.
      View in: PubMed
    51. Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020 04; 157(1):161-166. PMID: 31924334.
      View in: PubMed
    52. Santin AD, Filiaci V, Bellone S, Ratner ES, Mathews CA, Cantuaria G, Gunderson CC, Rutledge T, Buttin BM, Lankes HA, Frumovitz M, Khleif SN, Huh WK, Birrer MJ. Phase II evaluation of copanlisib, a selective inhibitor of Pi3kca, in patients with persistent or recurrent endometrial carcinoma harboring PIK3CA hotspot mutations: An NRG Oncology study (NRG-GY008). Gynecol Oncol Rep. 2020 Feb; 31:100532. PMID: 31934607.
      View in: PubMed
    53. Makhlouf H, Watson MA, Lankes HA, Weil C, Dickler M, Birrer M, Moskaluk C, Ramirez NC, Okby N, Alonsozana E, Barnes M, Goldman EB, Enos R, Lubensky I. Toward Improving Practices for Submission of Diagnostic Tissue Blocks for National Cancer Institute Clinical Trials. Am J Clin Pathol. 2020 01 02; 153(2):149-155. PMID: 31613330.
      View in: PubMed
    54. Schwede M, Waldron L, Mok SC, Wei W, Basunia A, Merritt MA, Mitsiades CS, Parmigiani G, Harrington DP, Quackenbush J, Birrer MJ, Culhane AC. The Impact of Stroma Admixture on Molecular Subtypes and Prognostic Gene Signatures in Serous Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2020 02; 29(2):509-519. PMID: 31871106.
      View in: PubMed
    55. Arend RC, Davis AM, Chimiczewski P, O'Malley DM, Provencher D, Vergote I, Ghamande S, Birrer MJ. EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer. Gynecol Oncol. 2020 02; 156(2):301-307. PMID: 31870556.
      View in: PubMed
    56. Arend R, Martinez A, Szul T, Birrer MJ. Biomarkers in ovarian cancer: To be or not to be. Cancer. 2019 12 15; 125 Suppl 24:4563-4572. PMID: 31967683.
      View in: PubMed
    57. Krill L, Deng W, Eskander R, Mutch D, Zweizig S, Hoang B, Ioffe O, Randall L, Lankes H, Miller DS, Birrer M. Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2020 02; 156(2):423-429. PMID: 31843273.
      View in: PubMed
    58. Myers AP, Konstantinopoulos PA, Barry WT, Luo W, Broaddus RR, Makker V, Drapkin R, Liu J, Doyle A, Horowitz NS, Meric-Bernstam F, Birrer M, Aghajanian C, Coleman RL, Mills GB, Cantley LC, Matulonis UA, Westin SN. Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer. 2020 07 15; 147(2):413-422. PMID: 31714586.
      View in: PubMed
    59. Oza AM, Matulonis UA, Alvarez Secord A, Nemunaitis J, Roman LD, Blagden SP, Banerjee S, McGuire WP, Ghamande S, Birrer MJ, Fleming GF, Markham MJ, Hirte HW, Provencher DM, Basu B, Kristeleit R, Armstrong DK, Schwartz B, Braly P, Hall GD, Nephew KP, Jueliger S, Oganesian A, Naim S, Hao Y, Keer H, Azab M, Matei D. A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res. 2020 03 01; 26(5):1009-1016. PMID: 31831561.
      View in: PubMed
    60. Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):420-428. PMID: 31623857.
      View in: PubMed
    61. Mirza MR, ?vall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, Anttila M, Werner TL, Lund B, Lindahl G, Hietanen S, Peen U, Dimoula M, Roed H, ?r Knudsen A, Staff S, Krog Vistisen A, Bj?rge L, M?enp?? JU. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol. 2019 10; 20(10):1409-1419. PMID: 31474354.
      View in: PubMed
    62. Lee EK, Tan-Wasielewski Z, Matulonis UA, Birrer MJ, Wright AA, Horowitz N, Konstantinopoulos PA, Curtis J, Liu JF. Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol Rep. 2019 Aug; 29:118-122. PMID: 31467965.
      View in: PubMed
    63. Mirza MR, Bergmann TK, Mau-S?rensen M, Christensen RD, ?vall-Lundqvist E, Birrer MJ, J?rgensen M, Roed H, Malander S, Nielsen F, Lassen U, Br?sen K, Bj?rge L, M?enp?? J. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemother Pharmacol. 2019 10; 84(4):791-798. PMID: 31375879.
      View in: PubMed
    64. Yeung TL, Leung CS, Yip KP, Sheng J, Vien L, Bover LC, Birrer MJ, Wong STC, Mok SC. Anticancer Immunotherapy by MFAP5 Blockade Inhibits Fibrosis and Enhances Chemosensitivity in Ovarian and Pancreatic Cancer. Clin Cancer Res. 2019 11 01; 25(21):6417-6428. PMID: 31332047.
      View in: PubMed
    65. Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, Raspagliesi F, Sonke GS, Birrer M, Provencher DM, Sehouli J, Colombo N, Gonz?lez-Mart?n A, Oaknin A, Ottevanger PB, Rudaitis V, Katchar K, Wu H, Keefe S, Ruman J, Ledermann JA. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019 07 01; 30(7):1080-1087. PMID: 31046082.
      View in: PubMed
    66. Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer. J Clin Oncol. 2019 09 10; 37(26):2317-2328. PMID: 31216226.
      View in: PubMed
    67. Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-Drug Conjugate-Based Therapeutics: State of the Science. J Natl Cancer Inst. 2019 Jun 01; 111(6):538-549. PMID: 30859213.
      View in: PubMed
    68. Roane BM, Arend RC, Birrer MJ. Review: Targeting the Transforming Growth Factor-Beta Pathway in Ovarian Cancer. Cancers (Basel). 2019 May 14; 11(5). PMID: 31091744.
      View in: PubMed
    69. Ceppi L, Bardhan NM, Na Y, Siegel A, Rajan N, Fruscio R, Del Carmen MG, Belcher AM, Birrer MJ. Real-Time Single-Walled Carbon Nanotube-Based Fluorescence Imaging Improves Survival after Debulking Surgery in an Ovarian Cancer Model. ACS Nano. 2019 05 28; 13(5):5356-5365. PMID: 31009198.
      View in: PubMed
    70. Zaborowski MP, Lee K, Na YJ, Sammarco A, Zhang X, Iwanicki M, Cheah PS, Lin HY, Zinter M, Chou CY, Fulci G, Tannous BA, Lai CP, Birrer MJ, Weissleder R, Lee H, Breakefield XO. Methods for Systematic Identification of Membrane Proteins for Specific Capture of Cancer-Derived Extracellular Vesicles. Cell Rep. 2019 04 02; 27(1):255-268.e6. PMID: 30943406.
      View in: PubMed
    71. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 04 01; 30(4):551-557. PMID: 30753272.
      View in: PubMed
    72. Randall LM, Birrer MJ, Herzog TJ. Ovarian Cancer Maintenance: Practice-Changing Data Calls for Changing Practice. Oncologist. 2019 05; 24(5):576-579. PMID: 30894410.
      View in: PubMed
    73. Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, Mayer EL, O'Cearbhaill RE, Coleman RL, Kochupurakkal B, Whalen C, Curtis J, Farooq S, Luo W, Eismann J, Buss MK, Aghajanian C, Mills GB, Palakurthi S, Kirschmeier P, Liu J, Cantley LC, Kaufmann SH, Swisher EM, D'Andrea AD, Winer E, Wulf GM, Matulonis UA. Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 04; 20(4):570-580. PMID: 30880072.
      View in: PubMed
    74. Brooks RA, Tritchler DS, Darcy KM, Lankes HA, Salani R, Sperduto P, Guntupalli S, DiSilvestro P, Kesterson J, Olawaiye AB, Moxley K, Waggoner S, Santin A, Rader JS, Kizer NT, Thaker PH, Powell MA, Mutch DG, Birrer MJ, Goodfellow PJ. GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2019 05; 153(2):335-342. PMID: 30827726.
      View in: PubMed
    75. Krasner CN, Castro C, Penson RT, Roche M, Matulonis UA, Morgan MA, Drescher C, Armstrong DK, Wolfe JK, Lee H, Supko JG, Seiden M, Birrer MJ, Dizon DS. Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of M?llerian origin. Gynecol Oncol. 2019 05; 153(2):223-229. PMID: 30765148.
      View in: PubMed
    76. Birrer MJ, Betella I, Martin LP, Moore KN. Is Targeting the Folate Receptor in Ovarian Cancer Coming of Age? Oncologist. 2019 04; 24(4):425-429. PMID: 30635448.
      View in: PubMed
    77. Rauh-Hain JA, Hidrue MK, Gaccione P, Melamed A, Meyer LA, Keating NL, Giordano SH, Rice LW, Birrer MJ, Del Carmen MG. Variation in resource utilization associated with the surgical management of ovarian cancer. Gynecol Oncol. 2019 03; 152(3):587-593. PMID: 30579568.
      View in: PubMed
    78. Yeung TL, Tsai CC, Leung CS, Au Yeung CL, Thompson MS, Lu KH, Freedman RS, Birrer MJ, Wong KK, Mok SC. ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression. Cancers (Basel). 2018 Nov 22; 10(12). PMID: 30469497.
      View in: PubMed
    79. Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, Gilbert L, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK. Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. Clin Cancer Res. 2019 03 15; 25(6):1727-1736. PMID: 30413525.
      View in: PubMed
    80. Elias KM, Tsantoulis P, Tille JC, Vitonis A, Doyle LA, Hornick JL, Kaya G, Barnes L, Cramer DW, Puppa G, Stuckelberger S, Hooda J, Dietrich PY, Goggins M, Kerr CL, Birrer M, Hirsch MS, Drapkin R, Labidi-Galy SI. Primordial germ cells as a potential shared cell of origin for mucinous cystic neoplasms of the pancreas and mucinous ovarian tumors. J Pathol. 2018 12; 246(4):459-469. PMID: 30229909.
      View in: PubMed
    81. Moore KN, O'Malley DM, Vergote I, Martin LP, Gonzalez-Martin A, Malek K, Birrer MJ. Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer. Gynecol Oncol. 2018 10; 151(1):46-52. PMID: 30093227.
      View in: PubMed
    82. Chen GM, Kannan L, Geistlinger L, Kofia V, Safikhani Z, Gendoo DMA, Parmigiani G, Birrer M, Haibe-Kains B, Waldron L. Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma. Clin Cancer Res. 2018 10 15; 24(20):5037-5047. PMID: 30084834.
      View in: PubMed
    83. Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. Clin Cancer Res. 2018 08 15; 24(16):3928-3940. PMID: 29685880.
      View in: PubMed
    84. Banerjee S, Oza AM, Birrer MJ, Hamilton EP, Hasan J, Leary A, Moore KN, Mackowiak-Matejczyk B, Pikiel J, Ray-Coquard I, Trask P, Lin K, Schuth E, Vaze A, Choi Y, Marsters JC, Maslyar DJ, Lemahieu V, Wang Y, Humke EW, Liu JF. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 04 01; 29(4):917-923. PMID: 29401246.
      View in: PubMed
    85. Moore KN, Birrer MJ. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations. Oncologist. 2018 06; 23(6):697-703. PMID: 29593098.
      View in: PubMed
    86. Hyman DM, Rizvi N, Natale R, Armstrong DK, Birrer M, Recht L, Dotan E, Makker V, Kaley T, Kuruvilla D, Gribbin M, McDevitt J, Lai DW, Dar M. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. Clin Cancer Res. 2018 06 15; 24(12):2749-2757. PMID: 29559563.
      View in: PubMed
    87. Dizon DS, Dias-Santagata D, Bregar A, Sullivan L, Filipi J, DiTavi E, Miller L, Ellisen L, Birrer M, DelCarmen M. Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair-Deficient Endometrial Cancer and a Germline BRCA1 Mutation. Oncologist. 2018 06; 23(6):650-653. PMID: 29472312.
      View in: PubMed
    88. Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, Pautier P, Malek K, Birrer MJ. FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncol. 2018 Jul; 14(17):1669-1678. PMID: 29424243.
      View in: PubMed
    89. Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2018 02 07; 9(1):628. PMID: 29416025.
      View in: PubMed
    90. Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2017 12 18; 8(1):2166. PMID: 29255160.
      View in: PubMed
    91. Leung CS, Yeung TL, Yip KP, Wong KK, Ho SY, Mangala LS, Sood AK, Lopez-Berestein G, Sheng J, Wong ST, Birrer MJ, Mok SC. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance. J Clin Invest. 2018 02 01; 128(2):589-606. PMID: 29251630.
      View in: PubMed
    92. Noh K, Mangala LS, Han HD, Zhang N, Pradeep S, Wu SY, Ma S, Mora E, Rupaimoole R, Jiang D, Wen Y, Shahzad MMK, Lyons Y, Cho M, Hu W, Nagaraja AS, Haemmerle M, Mak CSL, Chen X, Gharpure KM, Deng H, Xiong W, Kingsley CV, Liu J, Jennings N, Birrer MJ, Bouchard RR, Lopez-Berestein G, Coleman RL, An Z, Sood AK. Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Rep. 2017 Dec 05; 21(10):2785-2795. PMID: 29212026.
      View in: PubMed
    93. Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res. 2018 02 15; 24(4):777-783. PMID: 29191972.
      View in: PubMed
    94. Hamilton CA, Miller A, Casablanca Y, Horowitz NS, Rungruang B, Krivak TC, Richard SD, Rodriguez N, Birrer MJ, Backes FJ, Geller MA, Quinn M, Goodheart MJ, Mutch DG, Kavanagh JJ, Maxwell GL, Bookman MA. Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol. 2018 02; 148(2):275-280. PMID: 29195926.
      View in: PubMed
    95. Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Vergote I, Ponte JF, Birrer MJ. A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2018 Jan; 14(2):123-136. PMID: 29098867.
      View in: PubMed
    96. Bais C, Mueller B, Brady MF, Mannel RS, Burger RA, Wei W, Marien KM, Kockx MM, Husain A, Birrer MJ. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. J Natl Cancer Inst. 2017 11 01; 109(11). PMID: 29059426.
      View in: PubMed
    97. Wei W, Giulia F, Luffer S, Kumar R, Wu B, Tavallai M, Bekele RT, Birrer MJ. How can molecular abnormalities influence our clinical approach. Ann Oncol. 2017 Nov 01; 28(suppl_8):viii16-viii24. PMID: 29232470.
      View in: PubMed
    98. Devor EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, Lankes HA, Thaker P, Argenta PA, Pearl ML, Zweizig SL, Mannel RS, Brown A, Ramirez NC, Ioffe OB, Park KJ, Creasman WT, Birrer MJ, Mutch D, Leslie KK. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 12; 147(3):648-653. PMID: 28969912.
      View in: PubMed
    99. Moore KN, Tritchler D, Kaufman KM, Lankes H, Quinn MCJ, Van Le L, Berchuck A, Backes FJ, Tewari KS, Lee RB, Kesterson JP, Wenham RM, Armstrong DK, Krivak TC, Bookman MA, Birrer MJ. Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):396-401. PMID: 28935272.
      View in: PubMed
    100. Martin LP, Konner JA, Moore KN, Seward SM, Matulonis UA, Perez RP, Su Y, Berkenblit A, Ruiz-Soto R, Birrer MJ. Characterization of folate receptor alpha (FRa) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRa-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017 11; 147(2):402-407. PMID: 28843653.
      View in: PubMed
    101. Oliver KE, Brady WE, Birrer M, Gershenson DM, Fleming G, Copeland LJ, Tewari K, Argenta PA, Mannel RS, Secord AA, Stephan JM, Mutch DG, Stehman FB, Muggia FM, Rose PG, Armstrong DK, Bookman MA, Burger RA, Farley JH. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecol Oncol. 2017 11; 147(2):243-249. PMID: 28807367.
      View in: PubMed
    102. Tsang TY, Wei W, Itamochi H, Tambouret R, Birrer MJ. Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target. Oncotarget. 2017 Nov 14; 8(57):96482-96495. PMID: 29228547.
      View in: PubMed
    103. Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663. PMID: 28756902.
      View in: PubMed
    104. Reyes HD, Miecznikowski J, Gonzalez-Bosquet J, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Stephan JM, Hanjani P, Guntupalli S, Tewari KS, Backes F, Ramirez N, Fleming GF, Filiaci V, Birrer MJ, Leslie KK. High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol. 2017 08; 146(2):247-253. PMID: 28532857.
      View in: PubMed
    105. Grabosch S, Tseng G, Edwards RP, Lankes HA, Moore K, Odunsi K, Vlad A, Ma T, Strange M, Brozick J, Lugade A, Omilian A, Bshara W, Stuckey AR, Walker JL, Birrer M. Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2017 07; 146(1):137-145. PMID: 28483269.
      View in: PubMed
    106. Moore KN, Borghaei H, O'Malley DM, Jeong W, Seward SM, Bauer TM, Perez RP, Matulonis UA, Running KL, Zhang X, Ponte JF, Ruiz-Soto R, Birrer MJ. Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor a-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017 Aug 15; 123(16):3080-3087. PMID: 28440955.
      View in: PubMed
    107. Tao Z, Dang X, Huang X, Muzumdar MD, Xu ES, Bardhan NM, Song H, Qi R, Yu Y, Li T, Wei W, Wyckoff J, Birrer MJ, Belcher AM, Ghoroghchian PP. Early tumor detection afforded by in?vivo imaging of near-infrared II fluorescence. Biomaterials. 2017 Jul; 134:202-215. PMID: 28482280.
      View in: PubMed
    108. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KKH, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N, Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balma?a J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg ?, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KBM, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, D?rk T, Dossus L, Duran M, D?rst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlertsen B, Ekici AB, Ellis S, Elvira M, Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilas G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, Garc?a MJ, Garcia-Barberan V, Gehrig A, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, H?kansson N, Hamann U, Hansen TVO, Harrington PA, Harris HR, Hauke J, Hein A, Henderson A, Hildebrandt MAT, Hillemanns P, Hodgson S, H?gdall CK, H?gdall E, Hogervorst FBL, Holland H, Hooning MJ, Hosking K, Huang RY, Hulick PJ, Hung J, Hunter DJ, Huntsman DG, Huzarski T, Imyanitov EN, Isaacs C, Iversen ES, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jernetz M, Jensen A, Jensen UB, John EM, Johnatty S, Jones ME, Kannisto P, Karlan BY, Karnezis A, Kast K, Kennedy CJ, Khusnutdinova E, Kiemeney LA, Kiiski JI, Kim SW, Kjaer SK, K?bel M, Kopperud RK, Kruse TA, Kupryjanczyk J, Kwong A, Laitman Y, Lambrechts D, Larra?aga N, Larson MC, Lazaro C, Le ND, Le Marchand L, Lee JW, Lele SB, Leminen A, Leroux D, Lester J, Lesueur F, Levine DA, Liang D, Liebrich C, Lilyquist J, Lipworth L, Lissowska J, Lu KH, Lubinnski J, Luccarini C, Lundvall L, Mai PL, Mendoza-Fandi?o G, Manoukian S, Massuger LFAG, May T, Mazoyer S, McAlpine JN, McGuire V, McLaughlin JR, McNeish I, Meijers-Heijboer H, Meindl A, Menon U, Mensenkamp AR, Merritt MA, Milne RL, Mitchell G, Modugno F, Moes-Sosnowska J, Moffitt M, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Nathanson KL, Nedergaard L, Ness RB, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Odunsi K, Olah E, Olopade OI, Olsson H, Olswold C, O'Malley DM, Ong KR, Onland-Moret NC, Orr N, Orsulic S, Osorio A, Palli D, Papi L, Park-Simon TW, Paul J, Pearce CL, Pedersen IS, Peeters PHM, Peissel B, Peixoto A, Pejovic T, Pelttari LM, Permuth JB, Peterlongo P, Pezzani L, Pfeiler G, Phillips KA, Piedmonte M, Pike MC, Piskorz AM, Poblete SR, Pocza T, Poole EM, Poppe B, Porteous ME, Prieur F, Prokofyeva D, Pugh E, Pujana MA, Pujol P, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rhiem K, Rice P, Richardson A, Robson M, Rodriguez GC, Rodr?guez-Antona C, Romm J, Rookus MA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Salvesen HB, Sandler DP, Schoemaker MJ, Senter L, Setiawan VW, Severi G, Sharma P, Shelford T, Siddiqui N, Side LE, Sieh W, Singer CF, Sobol H, Song H, Southey MC, Spurdle AB, Stadler Z, Steinemann D, Stoppa-Lyonnet D, Sucheston-Campbell LE, Sukiennicki G, Sutphen R, Sutter C, Swerdlow AJ, Szabo CI, Szafron L, Tan YY, Taylor JA, Tea MK, Teixeira MR, Teo SH, Terry KL, Thompson PJ, Thomsen LCV, Thull DL, Tihomirova L, Tinker AV, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691. PMID: 28346442.
      View in: PubMed
    109. Gockley A, Melamed A, Bregar AJ, Clemmer JT, Birrer M, Schorge JO, Del Carmen MG, Rauh-Hain JA. Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer. Obstet Gynecol. 2017 03; 129(3):439-447. PMID: 28178043.
      View in: PubMed
    110. Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017 03 01; 28(3):512-518. PMID: 27993796.
      View in: PubMed
    111. Xiao H, Qi R, Li T, Awuah SG, Zheng Y, Wei W, Kang X, Song H, Wang Y, Yu Y, Bird MA, Jing X, Yaffe MB, Birrer MJ, Ghoroghchian PP. Maximizing Synergistic Activity When Combining RNAi and Platinum-Based Anticancer Agents. J Am Chem Soc. 2017 03 01; 139(8):3033-3044. PMID: 28166401.
      View in: PubMed
    112. Yazinski SA, Comaills V, Buisson R, Genois MM, Nguyen HD, Ho CK, Todorova Kwan T, Morris R, Lauffer S, Nussenzweig A, Ramaswamy S, Benes CH, Haber DA, Maheswaran S, Birrer MJ, Zou L. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells. Genes Dev. 2017 02 01; 31(3):318-332. PMID: 28242626.
      View in: PubMed
    113. Moore KN, Martin LP, O'Malley DM, Matulonis UA, Konner JA, Perez RP, Bauer TM, Ruiz-Soto R, Birrer MJ. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 01; 35(10):1112-1118. PMID: 28029313.
      View in: PubMed
    114. Liu JF, Moore KN, Birrer MJ, Berlin S, Matulonis UA, Infante JR, Wolpin B, Poon KA, Firestein R, Xu J, Kahn R, Wang Y, Wood K, Darbonne WC, Lackner MR, Kelley SK, Lu X, Choi YJ, Maslyar D, Humke EW, Burris HA. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 11; 27(11):2124-2130. PMID: 27793850.
      View in: PubMed
    115. McCourt CK, Deng W, Dizon DS, Lankes HA, Birrer MJ, Lomme MM, Powell MA, Kendrick JE, Saltzman JN, Warshal D, Tenney ME, Kushner DM, Aghajanian C. A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 Jan; 144(1):101-106. PMID: 28029447.
      View in: PubMed
    116. Lax T, Dizon DS, Birrer M, Long A, Del Carmen M, Goodman A, Krasner C, Penson RT, Growdon W, Camargo CA, Banerji A. Extended carboplatin infusion does not reduce frequency of hypersensitivity reaction at initiation of retreatment in patients with recurrent platinum-sensitive ovarian cancer. J Allergy Clin Immunol Pract. 2017 Jan - Feb; 5(1):177-178. PMID: 27641482.
      View in: PubMed
    117. Del Carmen MG, Supko JG, Horick NK, Rauh-Hain JA, Clark RM, Campos SM, Krasner CN, Atkinson T, Birrer MJ. Phase 1 and 2 study of carboplatin and pralatrexate in patients with recurrent, platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer. Cancer. 2016 Nov 15; 122(21):3297-3306. PMID: 27421044.
      View in: PubMed
    118. Wilbur MB, Birrer MJ, Spriggs DR. CLINICAL DECISIONS. Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Jul 14; 375(2):177-9. PMID: 27410928.
      View in: PubMed
    119. Waldron L, Riester M, Ramos M, Parmigiani G, Birrer M. The Doppelg?nger Effect: Hidden Duplicates in Databases of Transcriptome Profiles. J Natl Cancer Inst. 2016 11; 108(11). PMID: 27381624.
      View in: PubMed
    120. Rauh-Hain JA, Birrer M, Del Carmen MG. "Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities". Gynecol Oncol. 2016 Aug; 142(2):248-54. PMID: 27321238.
      View in: PubMed
    121. Sosulski A, Horn H, Zhang L, Coletti C, Vathipadiekal V, Castro CM, Birrer MJ, Nagano O, Saya H, Lage K, Donahoe PK, P?pin D. CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis. PLoS One. 2016; 11(6):e0156595. PMID: 27253518.
      View in: PubMed
    122. Sarantopoulos J, Mita MM, Birrer MJ, Cranmer LD, Campos LT, Zhang X, Bristow P, Kaito H, Strout V, Camacho LH. Phase 1 Study of Monotherapy with KHK2866, an Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor Monoclonal Antibody, in Patients with Advanced Cancer. Target Oncol. 2016 06; 11(3):317-27. PMID: 26507836.
      View in: PubMed
    123. Del Campo JM, Birrer M, Davis C, Fujiwara K, Gollerkeri A, Gore M, Houk B, Lau S, Poveda A, Gonz?lez-Mart?n A, Muller C, Muro K, Pierce K, Suzuki M, Vermette J, Oza A. A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecol Oncol. 2016 Jul; 142(1):62-69. PMID: 27103175.
      View in: PubMed
    124. Myers AP, Filiaci VL, Zhang Y, Pearl M, Behbakht K, Makker V, Hanjani P, Zweizig S, Burke JJ, Downey G, Leslie KK, Van Hummelen P, Birrer MJ, Fleming GF. Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Apr; 141(1):43-8. PMID: 27016228.
      View in: PubMed
    125. Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Yi Q, Burger RA, Chan JK, Davidson SA, Mannel RS, DiSilvestro PA, Lankes HA, Ramirez NC, King MC, Swisher EM, Birrer MJ. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2016 Apr; 2(4):482-90. PMID: 26720728.
      View in: PubMed
    126. Krzystyniak J, Ceppi L, Dizon DS, Birrer MJ. Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer. Ann Oncol. 2016 04; 27 Suppl 1:i4-i10. PMID: 27141069.
      View in: PubMed
    127. Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, Dizon DS, Birrer MJ. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Gynecol Oncol. 2016 Apr; 141(1):108-12. PMID: 27016236.
      View in: PubMed
    128. Swisher EM, Harrell MI, Norquist BM, Walsh T, Brady M, Lee M, Hershberg R, Kalli KR, Lankes H, Konnick EQ, Pritchard CC, Monk BJ, Chan JK, Burger R, Kaufmann SH, Birrer MJ. Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. JAMA Oncol. 2016 Mar; 2(3):370-2. PMID: 26847329.
      View in: PubMed
    129. Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O'Malley DM, Boente MP, Michael H, Monk BJ. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med. 2016 Feb 25; 374(8):738-48. PMID: 26933849.
      View in: PubMed
    130. van der Watt PJ, Chi A, Stelma T, Stowell C, Strydom E, Carden S, Angus L, Hadley K, Lang D, Wei W, Birrer MJ, Trent JO, Leaner VD. Targeting the Nuclear Import Receptor Kpn?1 as an Anticancer Therapeutic. Mol Cancer Ther. 2016 04; 15(4):560-73. PMID: 26832790.
      View in: PubMed
    131. Dizon DS, Birrer MJ. Making a Difference: Distinguishing Two Primaries From Metastasis in Synchronous Tumors of the Ovary and Uterus. J Natl Cancer Inst. 2016 Jun; 108(6):djv442. PMID: 26832772.
      View in: PubMed
    132. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, D?rst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA. Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2016 Jan; 48(1):101. PMID: 26711112.
      View in: PubMed
    133. Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ, Samimi G. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer. Oncotarget. 2015 Dec 29; 6(42):44551-62. PMID: 26575166.
      View in: PubMed
    134. Ye H, Tanenbaum LM, Na YJ, Mantzavinou A, Fulci G, Del Carmen MG, Birrer MJ, Cima MJ. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. J Control Release. 2015 Dec 28; 220(Pt A):358-367. PMID: 26548976.
      View in: PubMed
    135. Bowtell DD, B?hm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov; 15(11):668-79. PMID: 26493647.
      View in: PubMed
    136. Richards EJ, Permuth-Wey J, Li Y, Chen YA, Coppola D, Reid BM, Lin HY, Teer JK, Berchuck A, Birrer MJ, Lawrenson K, Monteiro AN, Schildkraut JM, Goode EL, Gayther SA, Sellers TA, Cheng JQ. A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer. Oncotarget. 2015 Oct 27; 6(33):34745-57. PMID: 26430965.
      View in: PubMed
    137. P?pin D, Sosulski A, Zhang L, Wang D, Vathipadiekal V, Hendren K, Coletti CM, Yu A, Castro CM, Birrer MJ, Gao G, Donahoe PK. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. Proc Natl Acad Sci U S A. 2015 Aug 11; 112(32):E4418-27. PMID: 26216943.
      View in: PubMed
    138. Wei W, Birrer MJ. Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer. Cancer Cell. 2015 Jul 13; 28(1):7-9. PMID: 26175410.
      View in: PubMed
    139. Elagib KE, Xiao M, Hussaini IM, Delehanty LL, Palmer LA, Racke FK, Birrer MJ, Ganapathy-Kanniappan S, McDevitt MA, Goldfarb AN. Erratum for Elagib et al., Jun Blockade of Erythropoiesis: Role for Repression of GATA-1 by HERP2. Mol Cell Biol. 2015 Jun; 35(12):2215. PMID: 25987232.
      View in: PubMed
    140. Vathipadiekal V, Wang V, Wei W, Waldron L, Drapkin R, Gillette M, Skates S, Birrer M. Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array. Clin Cancer Res. 2015 Nov 01; 21(21):4960-9. PMID: 25944803.
      View in: PubMed
    141. Tyekucheva S, Martin NE, Stack EC, Wei W, Vathipadiekal V, Waldron L, Fiorentino M, Lis RT, Stampfer MJ, Loda M, Parmigiani G, Mucci LA, Birrer M. Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. J Mol Diagn. 2015 Jul; 17(4):374-81. PMID: 25937617.
      View in: PubMed
    142. Bradford LS, Rauh-Hain JA, Schorge J, Birrer MJ, Dizon DS. Advances in the management of recurrent endometrial cancer. Am J Clin Oncol. 2015 Apr; 38(2):206-12. PMID: 23764681.
      View in: PubMed
    143. Castro CM, Im H, Le C, Lee H, Weissleder R, Birrer MJ. Exploring alternative ovarian cancer biomarkers using innovative nanotechnology strategies. Cancer Metastasis Rev. 2015 Mar; 34(1):75-82. PMID: 25543192.
      View in: PubMed
    144. Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res. 2015 Feb 15; 21(4):808-18. PMID: 25524310.
      View in: PubMed
    145. Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, Campana F, Xu Y, Egile C, Ghamande S. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015 Feb; 136(2):246-53. PMID: 25528496.
      View in: PubMed
    146. Leung CS, Yeung TL, Yip KP, Pradeep S, Balasubramanian L, Liu J, Wong KK, Mangala LS, Armaiz-Pena GN, Lopez-Berestein G, Sood AK, Birrer MJ, Mok SC. Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential. Nat Commun. 2014 Oct 03; 5:5092. PMID: 25277212.
      View in: PubMed
    147. Waldron L, Riester M, Birrer M. Molecular subtypes of high-grade serous ovarian cancer: the holy grail? J Natl Cancer Inst. 2014 Oct; 106(10). PMID: 25269490.
      View in: PubMed
    148. Ghosh D, Bagley AF, Na YJ, Birrer MJ, Bhatia SN, Belcher AM. Deep, noninvasive imaging and surgical guidance of submillimeter tumors using targeted M13-stabilized single-walled carbon nanotubes. Proc Natl Acad Sci U S A. 2014 Sep 23; 111(38):13948-53. PMID: 25214538.
      View in: PubMed
    149. Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct; 15(11):1207-14. PMID: 25218906.
      View in: PubMed
    150. Dizon DS, Birrer MJ. Advances in the diagnosis and treatment of uterine sarcomas. Discov Med. 2014 Jun; 17(96):339-45. PMID: 24979254.
      View in: PubMed
    151. Waldron L, Haibe-Kains B, Culhane AC, Riester M, Ding J, Wang XV, Ahmadifar M, Tyekucheva S, Bernau C, Risch T, Ganzfried BF, Huttenhower C, Birrer M, Parmigiani G. Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst. 2014 Apr 03; 106(5). PMID: 24700801.
      View in: PubMed
    152. Riester M, Wei W, Waldron L, Culhane AC, Trippa L, Oliva E, Kim SH, Michor F, Huttenhower C, Parmigiani G, Birrer MJ. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst. 2014 Apr 03; 106(5). PMID: 24700803.
      View in: PubMed
    153. Bookman MA, Gilks CB, Kohn EC, Kaplan KO, Huntsman D, Aghajanian C, Birrer MJ, Ledermann JA, Oza AM, Swenerton KD. Better therapeutic trials in ovarian cancer. J Natl Cancer Inst. 2014 Apr; 106(4):dju029. PMID: 24627272.
      View in: PubMed
    154. Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DSL, Mills GB, Sood A, Lee JS. Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer. Anticancer Res. 2014 Feb; 34(2):811-817. PMID: 24511017.
      View in: PubMed
    155. Birrer MJ. Ovarian cancer: targeting the untargetable. Am Soc Clin Oncol Educ Book. 2014; 13-5. PMID: 24857054.
      View in: PubMed
    156. Peterson VM, Castro CM, Chung J, Miller NC, Ullal AV, Castano MD, Penson RT, Lee H, Birrer MJ, Weissleder R. Ascites analysis by a microfluidic chip allows tumor-cell profiling. Proc Natl Acad Sci U S A. 2013 Dec 17; 110(51):E4978-86. PMID: 24297935.
      View in: PubMed
    157. Wei W, Dizon D, Vathipadiekal V, Birrer MJ. Ovarian cancer: genomic analysis. Ann Oncol. 2013 Dec; 24 Suppl 10:x7-15. PMID: 24265410.
      View in: PubMed
    158. Tanwar PS, Mohapatra G, Chiang S, Engler DA, Zhang L, Kaneko-Tarui T, Ohguchi Y, Birrer MJ, Teixeira JM. Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer. Carcinogenesis. 2014 Mar; 35(3):546-53. PMID: 24170201.
      View in: PubMed
    159. Creutzberg CL, Kitchener HC, Birrer MJ, Landoni F, Lu KH, Powell M, Aghajanian C, Edmondson R, Goodfellow PJ, Quinn M, Salvesen HB, Thomas G. Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: taking endometrial cancer trials into the translational era. Int J Gynecol Cancer. 2013 Oct; 23(8):1528-34. PMID: 24257568.
      View in: PubMed
    160. Levanon K, Sapoznik S, Bahar-Shany K, Brand H, Shapira-Frommer R, Korach J, Hirsch MS, Roh MH, Miron A, Liu JF, Vena N, Ligon AH, Fotheringham S, Bailey D, Flavin RJ, Birrer MJ, Drapkin RI. FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis. Oncogene. 2014 Aug 28; 33(35):4424-32. PMID: 24077281.
      View in: PubMed
    161. He L, Guo L, Vathipadiekal V, Sergent PA, Growdon WB, Engler DA, Rueda BR, Birrer MJ, Orsulic S, Mohapatra G. Identification of LMX1B as a novel oncogene in human ovarian cancer. Oncogene. 2014 Aug 14; 33(33):4226-35. PMID: 24056967.
      View in: PubMed
    162. Wei W, Mok SC, Oliva E, Kim SH, Mohapatra G, Birrer MJ. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest. 2013 Oct; 123(10):4435-48. PMID: 24018557.
      View in: PubMed
    163. Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS. Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2013 Sep; 23(7):1219-25. PMID: 23975042.
      View in: PubMed
    164. Penson RT, Dizon DS, Birrer MJ. Clear cell cancer of the ovary. Curr Opin Oncol. 2013 Sep; 25(5):553-7. PMID: 23942300.
      View in: PubMed
    165. Yeung TL, Leung CS, Wong KK, Samimi G, Thompson MS, Liu J, Zaid TM, Ghosh S, Birrer MJ, Mok SC. TGF-? modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 2013 Aug 15; 73(16):5016-28. PMID: 23824740.
      View in: PubMed
    166. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8. PMID: 23810467.
      View in: PubMed
    167. Holderness Parker N, Donninger H, Birrer MJ, Leaner VD. p21-activated kinase 3 (PAK3) is an AP-1 regulated gene contributing to actin organisation and migration of transformed fibroblasts. PLoS One. 2013; 8(6):e66892. PMID: 23818969.
      View in: PubMed
    168. Ganzfried BF, Riester M, Haibe-Kains B, Risch T, Tyekucheva S, Jazic I, Wang XV, Ahmadifar M, Birrer MJ, Parmigiani G, Huttenhower C, Waldron L. curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database (Oxford). 2013; 2013:bat013. PMID: 23550061.
      View in: PubMed
    169. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, Larson MC, Song H, Tessier DC, Bacot F, Vincent D, Cunningham JM, Dennis J, Dicks E, Aben KK, Anton-Culver H, Antonenkova N, Armasu SM, Baglietto L, Bandera EV, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brenton JD, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Campbell I, Carney ME, Carvalho RS, Chang-Claude J, Chen YA, Chen Z, Chow WH, Cicek MS, Coetzee G, Cook LS, Cramer DW, Cybulski C, Dansonka-Mieszkowska A, Despierre E, Doherty JA, D?rk T, du Bois A, D?rst M, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher D, Flanagan J, Gao YT, Garcia-Closas M, Gentry-Maharaj A, Giles G, Gjyshi A, Gore M, Gronwald J, Guo Q, Halle MK, Harter P, Hein A, Heitz F, Hillemanns P, Hoatlin M, H?gdall E, H?gdall CK, Hosono S, Jakubowska A, Jensen A, Kalli KR, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Konecny GE, Krakstad C, Kupryjanczyk J, Lambrechts D, Lambrechts S, Le ND, Lee N, Lee J, Leminen A, Lim BK, Lissowska J, Lubinski J, Lundvall L, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson S, Orlow I, Paul J, Pejovic T, Pelttari LM, Permuth-Wey J, Pike MC, Poole EM, Qu X, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum I, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shen H, Shridhar V, Shu XO, Sieh W, Southey MC, Spellman P, Tajima K, Teo SH, Terry KL, Thompson PJ, Timorek A, Tworoger SS, van Altena AM, van den Berg D, Vergote I, Vierkant RA, Vitonis AF, Wang-Gohrke S, Wentzensen N, Whittemore AS, Wik E, Winterhoff B, Woo YL, Wu AH, Yang HP, Zheng W, Ziogas A, Zulkifli F, Goodman MT, Hall P, Easton DF, Pearce CL, Berchuck A, Chenevix-Trench G, Iversen E, Monteiro AN, Gayther SA, Schildkraut JM, Sellers TA. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013 Apr; 45(4):362-70, 370e1-2. PMID: 23535730.
      View in: PubMed
    170. Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer. 2013 Apr 02; 108(6):1231-7. PMID: 23462720.
      View in: PubMed
    171. Schreiber S, Kerbrat M, Huthwelker T, Birrer M, Ammann M. Coupling a Knudsen reactor with the short lived radioactive tracer (13)N for atmospheric chemistry studies. Rev Sci Instrum. 2013 Mar; 84(3):035101. PMID: 23556846.
      View in: PubMed
    172. Goode EL, DeRycke M, Kalli KR, Oberg AL, Cunningham JM, Maurer MJ, Fridley BL, Armasu SM, Serie DJ, Ramar P, Goergen K, Vierkant RA, Rider DN, Sicotte H, Wang C, Winterhoff B, Phelan CM, Schildkraut JM, Weber RP, Iversen E, Berchuck A, Sutphen R, Birrer MJ, Hampras S, Preus L, Gayther SA, Ramus SJ, Wentzensen N, Yang HP, Garcia-Closas M, Song H, Tyrer J, Pharoah PP, Konecny G, Sellers TA, Ness RB, Sucheston LE, Odunsi K, Hartmann LC, Moysich KB, Knutson KL. Inherited variants in regulatory T cell genes and outcome of ovarian cancer. PLoS One. 2013; 8(1):e53903. PMID: 23382860.
      View in: PubMed
    173. Zaid TM, Yeung TL, Thompson MS, Leung CS, Harding T, Co NN, Schmandt RS, Kwan SY, Rodriguez-Aguay C, Lopez-Berestein G, Sood AK, Wong KK, Birrer MJ, Mok SC. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res. 2013 Feb 15; 19(4):809-20. PMID: 23344261.
      View in: PubMed
    174. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ, Cicek MS, Coetzee GA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Dansonka-Mieszkowska A, Despierre E, Doherty JA, D?rk T, du Bois A, D?rst M, Easton DF, Eccles D, Edwards R, Ekici AB, Fasching PA, Fenstermacher DA, Flanagan JM, Garcia-Closas M, Gentry-Maharaj A, Giles GG, Glasspool RM, Gonzalez-Bosquet J, Goodman MT, Gore M, G?rski B, Gronwald J, Hall P, Halle MK, Harter P, Heitz F, Hillemanns P, Hoatlin M, H?gdall CK, H?gdall E, Hosono S, Jakubowska A, Jensen A, Jim H, Kalli KR, Karlan BY, Kaye SB, Kelemen LE, Kiemeney LA, Kikkawa F, Konecny GE, Krakstad C, Kjaer SK, Kupryjanczyk J, Lambrechts D, Lambrechts S, Lancaster JM, Le ND, Leminen A, Levine DA, Liang D, Lim BK, Lin J, Lissowska J, Lu KH, Lubinski J, Lurie G, Massuger LF, Matsuo K, McGuire V, McLaughlin JR, Menon U, Modugno F, Moysich KB, Nakanishi T, Narod SA, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Noushmehr H, Odunsi K, Olson SH, Orlow I, Paul J, Pearce CL, Pejovic T, Pelttari LM, Pike MC, Poole EM, Raska P, Renner SP, Risch HA, Rodriguez-Rodriguez L, Rossing MA, Rudolph A, Runnebaum IB, Rzepecka IK, Salvesen HB, Schwaab I, Severi G, Shridhar V, Shu XO, Shvetsov YB, Sieh W, Song H, Southey MC, Spiewankiewicz B, Stram D, Sutphen R, Teo SH, Terry KL, Tessier DC, Thompson PJ, Tworoger SS, van Altena AM, Vergote I, Vierkant RA, Vincent D, Vitonis AF, Wang-Gohrke S, Palmieri Weber R, Wentzensen N, Whittemore AS, Wik E, Wilkens LR, Winterhoff B, Woo YL, Wu AH, Xiang YB, Yang HP, Zheng W, Ziogas A, Zulkifli F, Phelan CM, Iversen E, Schildkraut JM, Berchuck A, Fridley BL, Goode EL, Pharoah PD, Monteiro AN, Sellers TA, Gayther SA. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun. 2013; 4:1627. PMID: 23535648.
      View in: PubMed
    175. Verhaak RG, Tamayo P, Yang JY, Hubbard D, Zhang H, Creighton CJ, Fereday S, Lawrence M, Carter SL, Mermel CH, Kostic AD, Etemadmoghadam D, Saksena G, Cibulskis K, Duraisamy S, Levanon K, Sougnez C, Tsherniak A, Gomez S, Onofrio R, Gabriel S, Chin L, Zhang N, Spellman PT, Zhang Y, Akbani R, Hoadley KA, Kahn A, K?bel M, Huntsman D, Soslow RA, Defazio A, Birrer MJ, Gray JW, Weinstein JN, Bowtell DD, Drapkin R, Mesirov JP, Getz G, Levine DA, Meyerson M. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest. 2013 Jan; 123(1):517-25. PMID: 23257362.
      View in: PubMed
    176. Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, Mannel R, Yamada SD, Mutch D, Rodgers WH, Birrer M, Gershenson DM. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol. 2013 Feb; 14(2):134-40. PMID: 23261356.
      View in: PubMed
    177. May T, Shoni M, Crum CP, Xian W, Vathipadiekal V, Birrer M, Rosen B, Tone A, Murphy KJ. Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles. Gynecol Oncol. 2013 Mar; 128(3):488-92. PMID: 23253401.
      View in: PubMed
    178. Sethi G, Pathak HB, Zhang H, Zhou Y, Einarson MB, Vathipadiekal V, Gunewardena S, Birrer MJ, Godwin AK. An RNA interference lethality screen of the human druggable genome to identify molecular vulnerabilities in epithelial ovarian cancer. PLoS One. 2012; 7(10):e47086. PMID: 23056589.
      View in: PubMed
    179. del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol. 2012 Dec; 127(3):651-61. PMID: 23000148.
      View in: PubMed
    180. Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, Hua X, Landen CN, Birrer MJ, S?nchez-Beato M, Zhang R. SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK. Mol Cancer Res. 2012 Nov; 10(11):1462-72. PMID: 22964433.
      View in: PubMed
    181. Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012 Jul 20; 30(21):2654-63. PMID: 22711857.
      View in: PubMed
    182. del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012 Sep; 126(3):481-90. PMID: 22525820.
      View in: PubMed
    183. Kassler S, Donninger H, Birrer MJ, Clark GJ. RASSF1A and the Taxol Response in Ovarian Cancer. Mol Biol Int. 2012; 2012:263267. PMID: 22548172.
      View in: PubMed
    184. Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, Allred SF, Gross J, Deavers MT, Kuo WL, Karlan BY, Rueda BR, Orsulic S, Gershenson DM, Birrer MJ, Gray JW, Mohapatra G. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLoS One. 2012; 7(2):e30996. PMID: 22355333.
      View in: PubMed
    185. Ferriss JS, Kim Y, Duska L, Birrer M, Levine DA, Moskaluk C, Theodorescu D, Lee JK. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. PLoS One. 2012; 7(2):e30550. PMID: 22348014.
      View in: PubMed
    186. White KL, Schildkraut JM, Palmieri RT, Iversen ES, Berchuck A, Vierkant RA, Rider DN, Charbonneau B, Cicek MS, Sutphen R, Birrer MJ, Pharoah PP, Song H, Tyrer J, Gayther SA, Ramus SJ, Wentzensen N, Yang HP, Garcia-Closas M, Phelan CM, Cunningham JM, Fridley BL, Sellers TA, Goode EL. Ovarian cancer risk associated with inherited inflammation-related variants. Cancer Res. 2012 Mar 01; 72(5):1064-9. PMID: 22282663.
      View in: PubMed
    187. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L, Birrer MJ. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PLoS One. 2012; 7(1):e29079. PMID: 22272227.
      View in: PubMed
    188. Stevens KN, Kelemen LE, Wang X, Fridley BL, Vierkant RA, Fredericksen Z, Armasu SM, Tsai YY, Berchuck A, Narod SA, Phelan CM, Sutphen R, Birrer MJ, Schildkraut JM, Sellers TA, Goode EL, Couch FJ. Common variation in Nemo-like kinase is associated with risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):523-8. PMID: 22253297.
      View in: PubMed
    189. Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M, Krivak TC. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 May; 125(2):421-6. PMID: 22261301.
      View in: PubMed
    190. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29; 365(26):2473-83. PMID: 22204724.
      View in: PubMed
    191. del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. Gynecol Oncol. 2012 Apr; 125(1):271-7. PMID: 22155675.
      View in: PubMed
    192. Li H, Bitler BG, Vathipadiekal V, Maradeo ME, Slifker M, Creasy CL, Tummino PJ, Cairns P, Birrer MJ, Zhang R. ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches. Cancer Prev Res (Phila). 2012 Mar; 5(3):484-91. PMID: 22144423.
      View in: PubMed
    193. McCann CK, Growdon WB, Kulkarni-Datar K, Curley MD, Friel AM, Proctor JL, Sheikh H, Deyneko I, Ferguson JA, Vathipadiekal V, Birrer MJ, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Macdougall JR, Rueda BR. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. PLoS One. 2011; 6(11):e28077. PMID: 22140510.
      View in: PubMed
    194. Bodurka DC, Deavers MT, Tian C, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer. 2012 Jun 15; 118(12):3087-94. PMID: 22072418.
      View in: PubMed
    195. Hagemann AR, Cadungog M, Hagemann IS, Hammond R, Adams SF, Chu CS, Rubin SC, Zhang L, Addya K, Birrer MJ, Gimotty PA, Coukos G. Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. Cancer Biol Ther. 2011 Aug 15; 12(4):357-66. PMID: 21785264.
      View in: PubMed
    196. Hagemann AR, Hagemann IS, Cadungog M, Hwang WT, Patel P, Lal P, Hammond R, Gimotty PA, Chu CS, Rubin SC, Birrer MJ, Powell DJ, Feldman MD, Coukos G. Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Cancer Biol Ther. 2011 Aug 15; 12(4):367-77. PMID: 21785280.
      View in: PubMed
    197. Bitler BG, Nicodemus JP, Li H, Cai Q, Wu H, Hua X, Li T, Birrer MJ, Godwin AK, Cairns P, Zhang R. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. Cancer Res. 2011 Oct 01; 71(19):6184-94. PMID: 21816908.
      View in: PubMed
    198. Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D, Kowalski M, Mingari MC, Vianello F, Birrer M, Orsulic S, Dranoff G, Poznansky MC. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011 Aug 15; 71(16):5522-5534. PMID: 21742774.
      View in: PubMed
    199. Stany MP, Vathipadiekal V, Ozbun L, Stone RL, Mok SC, Xue H, Kagami T, Wang Y, McAlpine JN, Bowtell D, Gout PW, Miller DM, Gilks CB, Huntsman DG, Ellard SL, Wang YZ, Vivas-Mejia P, Lopez-Berestein G, Sood AK, Birrer MJ. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One. 2011; 6(7):e21121. PMID: 21754983.
      View in: PubMed
    200. Permuth-Wey J, Chen Z, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Chanock SJ, Cramer DW, Cunningham JM, Fenstermacher D, Fridley BL, Garcia-Closas M, Gayther SA, Gentry-Maharaj A, Gonzalez-Bosquet J, Iversen E, Jim H, McLaughlin J, Menon U, Narod SA, Phelan CM, Ramus SJ, Risch H, Song H, Sutphen R, Terry KL, Tyrer J, Vierkant RA, Wentzensen N, Lancaster JM, Cheng JQ, Berchuck A, Pharoah PD, Schildkraut JM, Goode EL, Sellers TA. MicroRNA processing and binding site polymorphisms are not replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2011 Aug; 20(8):1793-7. PMID: 21636674.
      View in: PubMed
    201. King ER, Tung CS, Tsang YT, Zu Z, Lok GT, Deavers MT, Malpica A, Wolf JK, Lu KH, Birrer MJ, Mok SC, Gershenson DM, Wong KK. The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer. Am J Surg Pathol. 2011 Jun; 35(6):904-12. PMID: 21451362.
      View in: PubMed
    202. Ledermann JA, Marth C, Carey MS, Birrer M, Bowtell DD, Kaye S, McNeish I, Oza A, Scambia G, Rustin G, Stehman FB, Gershenson D, Thomas G, Berns E, Casado A, Ottevanger N, Hilpert F, Kim BG, Okamoto A, Bacon M, Kitchener H, Stuart GC. Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer. 2011 May; 21(4):763-70. PMID: 21543938.
      View in: PubMed
    203. Helland ?, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Holm R, Kristensen GB, Birrer MJ, Pearson RB, B?rresen-Dale AL, Huntsman DG, deFazio A, Creighton CJ, Smyth GK, Bowtell DD. Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One. 2011 Apr 13; 6(4):e18064. PMID: 21533284.
      View in: PubMed
    204. Permuth-Wey J, Kim D, Tsai YY, Lin HY, Chen YA, Barnholtz-Sloan J, Birrer MJ, Bloom G, Chanock SJ, Chen Z, Cramer DW, Cunningham JM, Dagne G, Ebbert-Syfrett J, Fenstermacher D, Fridley BL, Garcia-Closas M, Gayther SA, Ge W, Gentry-Maharaj A, Gonzalez-Bosquet J, Goode EL, Iversen E, Jim H, Kong W, McLaughlin J, Menon U, Monteiro AN, Narod SA, Pharoah PD, Phelan CM, Qu X, Ramus SJ, Risch H, Schildkraut JM, Song H, Stockwell H, Sutphen R, Terry KL, Tyrer J, Vierkant RA, Wentzensen N, Lancaster JM, Cheng JQ, Sellers TA. LIN28B polymorphisms influence susceptibility to epithelial ovarian cancer. Cancer Res. 2011 Jun 01; 71(11):3896-903. PMID: 21482675.
      View in: PubMed
    205. Konstantinopoulos PA, Cannistra SA, Fountzilas H, Culhane A, Pillay K, Rueda B, Cramer D, Seiden M, Birrer M, Coukos G, Zhang L, Quackenbush J, Spentzos D. Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS One. 2011 Mar 29; 6(3):e18202. PMID: 21479231.
      View in: PubMed
    206. Maritz MF, van der Watt PJ, Holderness N, Birrer MJ, Leaner VD. Inhibition of AP-1 suppresses cervical cancer cell proliferation and is associated with p21 expression. Biol Chem. 2011 May; 392(5):439-48. PMID: 21417953.
      View in: PubMed
    207. Emmanuel C, Gava N, Kennedy C, Balleine RL, Sharma R, Wain G, Brand A, Hogg R, Etemadmoghadam D, George J, Birrer MJ, Clarke CL, Chenevix-Trench G, Bowtell DD, Harnett PR, deFazio A. Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS One. 2011 Mar 15; 6(3):e17617. PMID: 21423607.
      View in: PubMed
    208. Pharoah PD, Palmieri RT, Ramus SJ, Gayther SA, Andrulis IL, Anton-Culver H, Antonenkova N, Antoniou AC, Goldgar D, Beattie MS, Beckmann MW, Birrer MJ, Bogdanova N, Bolton KL, Brewster W, Brooks-Wilson A, Brown R, Butzow R, Caldes T, Caligo MA, Campbell I, Chang-Claude J, Chen YA, Cook LS, Couch FJ, Cramer DW, Cunningham JM, Despierre E, Doherty JA, D?rk T, D?rst M, Eccles DM, Ekici AB, Easton D, Fasching PA, de Fazio A, Fenstermacher DA, Flanagan JM, Fridley BL, Friedman E, Gao B, Sinilnikova O, Gentry-Maharaj A, Godwin AK, Goode EL, Goodman MT, Gross J, Hansen TV, Harnett P, Rookus M, Heikkinen T, Hein R, H?gdall C, H?gdall E, Iversen ES, Jakubowska A, Johnatty SE, Karlan BY, Kauff ND, Kaye SB, Chenevix-Trench G, Kelemen LE, Kiemeney LA, Kjaer SK, Lambrechts D, Lapolla JP, L?zaro C, Le ND, Leminen A, Leunen K, Levine DA, Lu Y, Lundvall L, Macgregor S, Marees T, Massuger LF, McLaughlin JR, Menon U, Montagna M, Moysich KB, Narod SA, Nathanson KL, Nedergaard L, Ness RB, Nevanlinna H, Nickels S, Osorio A, Paul J, Pearce CL, Phelan CM, Pike MC, Radice P, Rossing MA, Schildkraut JM, Sellers TA, Singer CF, Song H, Stram DO, Sutphen R, Lindblom A, Terry KL, Tsai YY, van Altena AM, Vergote I, Vierkant RA, Vitonis AF, Walsh C, Wang-Gohrke S, Wappenschmidt B, Wu AH, Ziogas A, Berchuck A, Risch HA. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res. 2011 Jun 01; 17(11):3742-50. PMID: 21385923.
      View in: PubMed
    209. Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, Power J, Coward J, Cowin PA, House CM, Chakravarty P, Gorringe KL, Campbell IG, Okamoto A, Birrer MJ, Huntsman DG, de Fazio A, Kalloger SE, Balkwill F, Gilks CB, Bowtell DD. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res. 2011 Apr 15; 17(8):2538-48. PMID: 21343371.
      View in: PubMed
    210. Farley J, Smith LM, Darcy KM, Brady MF, Bell J, McGuire W, Birrer MJ. Nuclear P27 expression in benign, borderline (LMP) and invasive tumors of the ovary and its association with prognosis: a gynecologic oncology group study. Gynecol Oncol. 2011 May 01; 121(2):395-401. PMID: 21310472.
      View in: PubMed
    211. Farley J, Sill MW, Birrer M, Walker J, Schilder RJ, Thigpen JT, Coleman RL, Miller BE, Rose PG, Lankes HA. Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 May 01; 121(2):303-8. PMID: 21329967.
      View in: PubMed
    212. Matei D, Sill MW, Lankes HA, DeGeest K, Bristow RE, Mutch D, Yamada SD, Cohn D, Calvert V, Farley J, Petricoin EF, Birrer MJ. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J Clin Oncol. 2011 Jan 01; 29(1):69-75. PMID: 21098323.
      View in: PubMed
    213. Huthwelker T, Zelenay V, Birrer M, Krepelova A, Raabe J, Tzvetkov G, Vernooij MG, Ammann M. An in situ cell to study phase transitions in individual aerosol particles on a substrate using scanning transmission x-ray microspectroscopy. Rev Sci Instrum. 2010 Nov; 81(11):113706. PMID: 21133477.
      View in: PubMed
    214. Birrer MJ. The origin of ovarian cancer?is it getting clearer? N Engl J Med. 2010 Oct 14; 363(16):1574-5. PMID: 20942676.
      View in: PubMed
    215. Trimble EL, Birrer MJ, Hoskins WJ, Marth C, Petryshyn R, Quinn M, Thomas GM, Kitchener HC, Aghajanian C, Alberts DS, Armstrong D, Brown J, Coleman RL, Colombo N, Eisenhauer E, Friedlander M, Fujiwara K, Hunsberger S, Kaye S, Ledermann JA, Lee S, Look K, Mannel R, McNeish IA, Minasian L, Oza A, Paul J, Poveda A, Pujade-Lauraine E, Schoenfeldt M, Swart AM, von Gruenigen V, Wenzel L. Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. Int J Gynecol Cancer. 2010 Oct; 20(7):1290-8. PMID: 21151709.
      View in: PubMed
    216. Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Takeda K, Aburatani H, Oizumi S, Konishi J, Kaga K, Matsuno Y, Birrer MJ, Nishimura M, Dosaka-Akita H. Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer. Lung Cancer. 2011 May; 72(2):229-37. PMID: 20884074.
      View in: PubMed
    217. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, Brewster W, Anton-Culver H, Ziogas A, Narod SA, Levine DA, Kaye SB, Brown R, Paul J, Flanagan J, Sieh W, McGuire V, Whittemore AS, Campbell I, Gore ME, Lissowska J, Yang HP, Medrek K, Gronwald J, Lubinski J, Jakubowska A, Le ND, Cook LS, Kelemen LE, Brooks-Wilson A, Brook-Wilson A, Massuger LF, Kiemeney LA, Aben KK, van Altena AM, Houlston R, Tomlinson I, Palmieri RT, Moorman PG, Schildkraut J, Iversen ES, Phelan C, Vierkant RA, Cunningham JM, Goode EL, Fridley BL, Kruger-Kjaer S, Blaeker J, Hogdall E, Hogdall C, Gross J, Karlan BY, Ness RB, Edwards RP, Odunsi K, Moyisch KB, Baker JA, Modugno F, Heikkinenen T, Butzow R, Nevanlinna H, Leminen A, Bogdanova N, Antonenkova N, Doerk T, Hillemanns P, D?rst M, Runnebaum I, Thompson PJ, Carney ME, Goodman MT, Lurie G, Wang-Gohrke S, Hein R, Chang-Claude J, Rossing MA, Cushing-Haugen KL, Doherty J, Chen C, Rafnar T, Besenbacher S, Sulem P, Stefansson K, Birrer MJ, Terry KL, Hernandez D, Cramer DW, Vergote I, Amant F, Lambrechts D, Despierre E, Fasching PA, Beckmann MW, Thiel FC, Ekici AB, Chen X, Johnatty SE, Webb PM, Beesley J, Chanock S, Garcia-Closas M, Sellers T, Easton DF, Berchuck A, Chenevix-Trench G, Pharoah PD, Gayther SA. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010 Oct; 42(10):880-4. PMID: 20852633.
      View in: PubMed
    218. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Widschwendter M, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, D?rk T, Nevanlinna H, Ness RB, Rafnar T, Hogdall C, Hogdall E, Fridley BL, Cunningham JM, Sieh W, McGuire V, Godwin AK, Cramer DW, Hernandez D, Levine D, Lu K, Iversen ES, Palmieri RT, Houlston R, van Altena AM, Aben KK, Massuger LF, Brooks-Wilson A, Kelemen LE, Le ND, Jakubowska A, Lubinski J, Medrek K, Stafford A, Easton DF, Tyrer J, Bolton KL, Harrington P, Eccles D, Chen A, Molina AN, Davila BN, Arango H, Tsai YY, Chen Z, Risch HA, McLaughlin J, Narod SA, Ziogas A, Brewster W, Gentry-Maharaj A, Menon U, Wu AH, Stram DO, Pike MC, Beesley J, Webb PM, Chen X, Ekici AB, Thiel FC, Beckmann MW, Yang H, Wentzensen N, Lissowska J, Fasching PA, Despierre E, Amant F, Vergote I, Doherty J, Hein R, Wang-Gohrke S, Lurie G, Carney ME, Thompson PJ, Runnebaum I, Hillemanns P, D?rst M, Antonenkova N, Bogdanova N, Leminen A, Butzow R, Heikkinen T, Stefansson K, Sulem P, Besenbacher S, Sellers TA, Gayther SA, Pharoah PD. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010 Oct; 42(10):874-9. PMID: 20852632.
      View in: PubMed
    219. Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, Ravoori MK, Shahzad MM, Lee JW, Mora E, Langley RR, Carroll AR, Matsuo K, Spannuth WA, Schmandt R, Jennings NB, Goodman BW, Jaffe RB, Nick AM, Kim HS, Guven EO, Chen YH, Li LY, Hsu MC, Coleman RL, Calin GA, Denkbas EB, Lim JY, Lee JS, Kundra V, Birrer MJ, Hung MC, Lopez-Berestein G, Sood AK. Regulation of tumor angiogenesis by EZH2. Cancer Cell. 2010 Aug 09; 18(2):185-97. PMID: 20708159.
      View in: PubMed
    220. Terry KL, Vitonis AF, Hernandez D, Lurie G, Song H, Ramus SJ, Titus-Ernstoff L, Carney ME, Wilkens LR, Gentry-Maharaj A, Menon U, Gayther SA, Pharaoh PD, Goodman MT, Cramer DW, Birrer MJ. A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies. Int J Mol Epidemiol Genet. 2010 Jul 26; 1(4):272-7. PMID: 21532840.
      View in: PubMed
    221. Annunziata CM, Birrer MJ. CD157 in ovarian carcinoma: how does it help us? J Natl Cancer Inst. 2010 Aug 04; 102(15):1104-5. PMID: 20639477.
      View in: PubMed
    222. Ghosh S, Albitar L, LeBaron R, Welch WR, Samimi G, Birrer MJ, Berkowitz RS, Mok SC. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol Oncol. 2010 Oct; 119(1):114-20. PMID: 20619446.
      View in: PubMed
    223. Annunziata CM, Stavnes HT, Kleinberg L, Berner A, Hernandez LF, Birrer MJ, Steinberg SM, Davidson B, Kohn EC. Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer. 2010 Jul 01; 116(13):3276-84. PMID: 20564628.
      View in: PubMed
    224. Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM. Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res. 2010 May 15; 70(10):4005-14. PMID: 20424119.
      View in: PubMed
    225. Darcy KM, Birrer MJ. Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol. 2010 Jun; 117(3):429-39. PMID: 20233625.
      View in: PubMed
    226. Huh WK, Sill MW, Darcy KM, Elias KM, Hoffman JS, Boggess JF, Alvarez RD, Long HJ, O'Malley DM, Birrer MJ. Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. Gynecol Oncol. 2010 May; 117(2):248-54. PMID: 20189232.
      View in: PubMed
    227. Clauss A, Ng V, Liu J, Piao H, Russo M, Vena N, Sheng Q, Hirsch MS, Bonome T, Matulonis U, Ligon AH, Birrer MJ, Drapkin R. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia. 2010 Feb; 12(2):161-72. PMID: 20126474.
      View in: PubMed
    228. Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, Pollock PM. FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol. 2010 Apr; 117(1):125-9. PMID: 20106510.
      View in: PubMed
    229. Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Risinger JI, Thigpen JT, Fleming GF, Gallion HH, Maxwell GL. Chemotherapy intensity and toxicity among black and white women with advanced and recurrent endometrial cancer: a Gynecologic Oncology Group Study. Cancer. 2010 Jan 15; 116(2):355-61. PMID: 19924790.
      View in: PubMed
    230. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell. 2009 Dec 08; 16(6):521-32. PMID: 19962670.
      View in: PubMed
    231. Na YJ, Farley J, Zeh A, del Carmen M, Penson R, Birrer MJ. Ovarian cancer: markers of response. Int J Gynecol Cancer. 2009 Dec; 19 Suppl 2:S21-9. PMID: 19955910.
      View in: PubMed
    232. Minig L, Trimble EL, Birrer MJ, Kim KY, Takebe N, Abrams JS. NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide. Gynecol Oncol. 2010 Feb; 116(2):177-80. PMID: 19889449.
      View in: PubMed
    233. Farley JH, Tian C, Rose GS, Brown CL, Birrer M, Maxwell GL. Race does not impact outcome for advanced ovarian cancer patients treated with cisplatin/paclitaxel: an analysis of Gynecologic Oncology Group trials. Cancer. 2009 Sep 15; 115(18):4210-7. PMID: 19536873.
      View in: PubMed
    234. Wang XY, Demelash A, Kim H, Jensen-Taubman S, Dakir el H, Ozbun L, Birrer MJ, Linnoila RI. Matrilysin-1 mediates bronchiolization of alveoli, a potential premalignant change in lung cancer. Am J Pathol. 2009 Aug; 175(2):592-604. PMID: 19608871.
      View in: PubMed
    235. Darcy KM, Brady WE, Blancato JK, Dickson RB, Hoskins WJ, McGuire WP, Birrer MJ. Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2009 Sep; 114(3):472-9. PMID: 19524285.
      View in: PubMed
    236. Kwong J, Chan FL, Wong KK, Birrer MJ, Archibald KM, Balkwill FR, Berkowitz RS, Mok SC. Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia. 2009 Jun; 11(6):529-41. PMID: 19484142.
      View in: PubMed
    237. Calvisi DF, Donninger H, Vos MD, Birrer MJ, Gordon L, Leaner V, Clark GJ. NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res. 2009 Jun 01; 69(11):4629-37. PMID: 19435914.
      View in: PubMed
    238. Wang B, Khachigian LM, Esau L, Birrer MJ, Zhao X, Parker MI, Hendricks DT. A key role for early growth response-1 and nuclear factor-kappaB in mediating and maintaining GRO/CXCR2 proliferative signaling in esophageal cancer. Mol Cancer Res. 2009 May; 7(5):755-64. PMID: 19435811.
      View in: PubMed
    239. van der Watt PJ, Maske CP, Hendricks DT, Parker MI, Denny L, Govender D, Birrer MJ, Leaner VD. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer. 2009 Apr 15; 124(8):1829-40. PMID: 19117056.
      View in: PubMed
    240. Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, Siu NS, Wong YM, Tsang PT, Pang MW, Yu MY, To KF, Mok SC, Wang VW, Li C, Cheung AY, Doran G, Birrer MJ, Smith DI, Wong YF. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer. 2009 Mar 15; 124(6):1358-65. PMID: 19065659.
      View in: PubMed
    241. Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, Reddy S, Farias-Eisner R. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol. 2009 Jun; 200(6):639.e1-5. PMID: 19285648.
      View in: PubMed
    242. Farley J, Fuchiuji S, Darcy KM, Tian C, Hoskins WJ, McGuire WP, Hanjani P, Warshal D, Greer BE, Belinson J, Birrer MJ. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol. 2009 Jun; 113(3):341-7. PMID: 19272639.
      View in: PubMed
    243. Singh S, Manda SM, Sikder D, Birrer MJ, Rothermel BA, Garry DJ, Mammen PP. Calcineurin activates cytoglobin transcription in hypoxic myocytes. J Biol Chem. 2009 Apr 17; 284(16):10409-21. PMID: 19203999.
      View in: PubMed
    244. Farley J, Birrer MJ. Novel therapeutic targets. Cancer Treat Res. 2009; 149:63-84. PMID: 19763431.
      View in: PubMed
    245. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, Schmandt R, Urbauer D, Pennacchio LA, Cheng JF, Nick AM, Deavers MT, Mourad-Zeidan A, Wang H, Mueller P, Lenburg ME, Gray JW, Mok S, Birrer MJ, Lopez-Berestein G, Coleman RL, Bar-Eli M, Sood AK. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med. 2008 Dec 18; 359(25):2641-50. PMID: 19092150.
      View in: PubMed
    246. Leaner VD, Chick JF, Donninger H, Linniola I, Mendoza A, Khanna C, Birrer MJ. Inhibition of AP-1 transcriptional activity blocks the migration, invasion, and experimental metastasis of murine osteosarcoma. Am J Pathol. 2009 Jan; 174(1):265-75. PMID: 19074613.
      View in: PubMed
    247. Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, Sullivan EH, Hirsch MS, Matulonis UA, Liu J, Birrer MJ, Berkowitz RS, Mok SC. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7667-73. PMID: 19047092.
      View in: PubMed
    248. Arora S, Wang Y, Jia Z, Vardar-Sengul S, Munawar A, Doctor KS, Birrer M, McClelland M, Adamson E, Mercola D. Egr1 regulates the coordinated expression of numerous EGF receptor target genes as identified by ChIP-on-chip. Genome Biol. 2008; 9(11):R166. PMID: 19032775.
      View in: PubMed
    249. Kikuchi J, Kinoshita I, Shimizu Y, Oizumi S, Nishimura M, Birrer MJ, Dosaka-Akita H. Simultaneous blockade of AP-1 and phosphatidylinositol 3-kinase pathway in non-small cell lung cancer cells. Br J Cancer. 2008 Dec 16; 99(12):2013-9. PMID: 19018257.
      View in: PubMed
    250. Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, Simms L, Locandro B, Fereday S, Traficante N, Russell P, Sharma R, Birrer MJ, deFazio A, Chenevix-Trench G, Bowtell DD. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res. 2008 Nov; 6(11):1678-90. PMID: 19010816.
      View in: PubMed
    251. Lorenzi PL, Llamas J, Gunsior M, Ozbun L, Reinhold WC, Varma S, Ji H, Kim H, Hutchinson AA, Kohn EC, Goldsmith PK, Birrer MJ, Weinstein JN. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther. 2008 Oct; 7(10):3123-8. PMID: 18852115.
      View in: PubMed
    252. Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, Wong KK. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia. 2008 Sep; 10(9):964-72. PMID: 18714397.
      View in: PubMed
    253. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC, Boyd J, Birrer MJ. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008 Jul 01; 68(13):5478-86. PMID: 18593951.
      View in: PubMed
    254. Sood AK, Birrer MJ. Highlights from the 2008 Annual Meeting of the American Association for Cancer Research. Gynecol Oncol. 2008 Jul; 110(1):5-6. PMID: 18595162.
      View in: PubMed
    255. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, B?tzow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A. 2008 May 13; 105(19):7004-9. PMID: 18458333.
      View in: PubMed
    256. Farley J, Ozbun LL, Birrer MJ. Genomic analysis of epithelial ovarian cancer. Cell Res. 2008 May; 18(5):538-48. PMID: 18427574.
      View in: PubMed
    257. Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecol Oncol. 2008 May; 109(2):234-9. PMID: 18331757.
      View in: PubMed
    258. Shimizu Y, Kinoshita I, Kikuchi J, Yamazaki K, Nishimura M, Birrer MJ, Dosaka-Akita H. Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant. Br J Cancer. 2008 Mar 11; 98(5):915-22. PMID: 18283312.
      View in: PubMed
    259. Zudaire E, Cuesta N, Murty V, Woodson K, Adams L, Gonzalez N, Mart?nez A, Narayan G, Kirsch I, Franklin W, Hirsch F, Birrer M, Cuttitta F. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest. 2008 Feb; 118(2):640-50. PMID: 18172554.
      View in: PubMed
    260. Landen CN, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol. 2008 Feb 20; 26(6):995-1005. PMID: 18195328.
      View in: PubMed
    261. Stany MP, Bonome T, Wamunyokoli F, Zorn K, Ozbun L, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, Berkowitz RS, Mok SC, Birrer MJ. Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol. 2008; 622:23-33. PMID: 18546616.
      View in: PubMed
    262. Irarrazabal CE, Williams CK, Ely MA, Birrer MJ, Garcia-Perez A, Burg MB, Ferraris JD. Activator protein-1 contributes to high NaCl-induced increase in tonicity-responsive enhancer/osmotic response element-binding protein transactivating activity. J Biol Chem. 2008 Feb 01; 283(5):2554-63. PMID: 18056707.
      View in: PubMed
    263. Whibley CE, McPhail KL, Keyzers RA, Maritz MF, Leaner VD, Birrer MJ, Davies-Coleman MT, Hendricks DT. Reactive oxygen species mediated apoptosis of esophageal cancer cells induced by marine triprenyl toluquinones and toluhydroquinones. Mol Cancer Ther. 2007 Sep; 6(9):2535-43. PMID: 17876050.
      View in: PubMed
    264. Kajanne R, Miettinen P, Mehlem A, Leivonen SK, Birrer M, Foschi M, K?h?ri VM, Lepp? S. EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol. 2007 Aug; 212(2):489-97. PMID: 17348021.
      View in: PubMed
    265. Gershenson DM, Birrer M. Time for action: a "sea change" in treatment strategies for rare types of epithelial ovarian cancer. Gynecol Oncol. 2007 Jul; 106(1):1-3. PMID: 17574071.
      View in: PubMed
    266. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol. 2007 Jun 01; 25(16):2281-7. PMID: 17538174.
      View in: PubMed
    267. Allen NP, Donninger H, Vos MD, Eckfeld K, Hesson L, Gordon L, Birrer MJ, Latif F, Clark GJ. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene. 2007 Sep 13; 26(42):6203-11. PMID: 17404571.
      View in: PubMed
    268. Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ, Sood AK. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 2007 Feb 15; 67(4):1757-68. PMID: 17308118.
      View in: PubMed
    269. Kelloff GJ, Sullivan DC, Baker H, Clarke LP, Nordstrom R, Tatum JL, Dorfman GS, Jacobs P, Berg CD, Pomper MG, Birrer MJ, Tempero M, Higley HR, Petty BG, Sigman CC, Maley C, Sharma P, Wax A, Ginsberg GG, Dannenberg AJ, Hawk ET, Messing EM, Grossman HB, Harisinghani M, Bigio IJ, Griebel D, Henson DE, Fabian CJ, Ferrara K, Fantini S, Schnall MD, Zujewski JA, Hayes W, Klein EA, DeMarzo A, Ocak I, Ketterling JA, Tempany C, Shtern F, Parnes HL, Gomez J, Srivastava S, Szabo E, Lam S, Seibel EJ, Massion P, McLennan G, Cleary K, Suh R, Burt RW, Pfeiffer RM, Hoffman JM, Roy HK, Wang T, Limburg PJ, El-Deiry WS, Papadimitrakopoulou V, Hittelman WN, MacAulay C, Veltri RW, Solomon D, Jeronimo J, Richards-Kortum R, Johnson KA, Viner JL, Stratton SP, Rajadhyaksha M, Dhawan A. Workshop on imaging science development for cancer prevention and preemption. Cancer Biomark. 2007; 3(1):1-33. PMID: 17655039.
      View in: PubMed
    270. Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers. 2007; 23(5-6):367-76. PMID: 18057520.
      View in: PubMed
    271. Samimi G, Ozbun L, Johnson ME, Mok SC, Birrer MJ. Biomarkers of mucinous tumors of the ovary. Dis Markers. 2007; 23(5-6):389-96. PMID: 18057522.
      View in: PubMed
    272. Farley J, Ozbun L, Samimi G, Birrer MJ. Cell cycle and related protein. Dis Markers. 2007; 23(5-6):433-43. PMID: 18057526.
      View in: PubMed
    273. Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res. 2007; 96:1-22. PMID: 17161674.
      View in: PubMed
    274. Wu K, Liu M, Li A, Donninger H, Rao M, Jiao X, Lisanti MP, Cvekl A, Birrer M, Pestell RG. Cell fate determination factor DACH1 inhibits c-Jun-induced contact-independent growth. Mol Biol Cell. 2007 Mar; 18(3):755-67. PMID: 17182846.
      View in: PubMed
    275. Wong YF, Cheung TH, Lo KW, Yim SF, Siu NS, Chan SC, Ho TW, Wong KW, Yu MY, Wang VW, Li C, Gardner GJ, Bonome T, Johnson WB, Smith DI, Chung TK, Birrer MJ. Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling. Oncogene. 2007 Mar 22; 26(13):1971-82. PMID: 17043662.
      View in: PubMed
    276. Fountain J, Trimble E, Birrer MJ. Summary and discussion of session recommendations. Gynecol Oncol. 2006 Nov; 103(2 Suppl 1):S23-5. PMID: 17027068.
      View in: PubMed
    277. Farley J, Bast RC, Birrer MJ. Biomarkers and clinical trial design. Gynecol Oncol. 2006 Nov; 103(2 Suppl 1):S3-5. PMID: 17027069.
      View in: PubMed
    278. Farley J, Birrer MJ, Christian MC. The future of phase II trials. Gynecol Oncol. 2006 Nov; 103(2 Suppl 1):S20-2. PMID: 17027074.
      View in: PubMed
    279. Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, Mok SC, Brady J, Bonome T, Birrer MJ. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res. 2006 Sep 01; 66(17):8404-12. PMID: 16951150.
      View in: PubMed
    280. Birrer MJ. Ovarian cancer: not a borderline issue! Cancer Biol Ther. 2006 Jul; 5(7):786-7. PMID: 16921259.
      View in: PubMed
    281. DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Martignetti JA. Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clin Cancer Res. 2006 Jun 15; 12(12):3730-9. PMID: 16778100.
      View in: PubMed
    282. Wamunyokoli FW, Bonome T, Lee JY, Feltmate CM, Welch WR, Radonovich M, Pise-Masison C, Brady J, Hao K, Berkowitz RS, Mok S, Birrer MJ. Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):690-700. PMID: 16467078.
      View in: PubMed
    283. Nummela P, Yin M, Kielosto M, Leaner V, Birrer MJ, H?ltt? E. Thymosin beta4 is a determinant of the transformed phenotype and invasiveness of S-adenosylmethionine decarboxylase-transfected fibroblasts. Cancer Res. 2006 Jan 15; 66(2):701-12. PMID: 16423999.
      View in: PubMed
    284. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 2005 Nov 15; 65(22):10602-12. PMID: 16288054.
      View in: PubMed
    285. Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6880-8. PMID: 16203778.
      View in: PubMed
    286. Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005 Sep 15; 11(18):6422-30. PMID: 16166416.
      View in: PubMed
    287. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005 Sep 01; 11(17):6300-10. PMID: 16144934.
      View in: PubMed
    288. Unterweger M, Froehlich JM, Kubik-Huch RA, Seifert B, Birrer M, Huber T, Otto R. Dose optimization of contrast-enhanced carotid MR angiography. Eur Radiol. 2005 Sep; 15(9):1797-805. PMID: 15875194.
      View in: PubMed
    289. Elam C, Hesson L, Vos MD, Eckfeld K, Ellis CA, Bell A, Krex D, Birrer MJ, Latif F, Clark GJ. RRP22 is a farnesylated, nucleolar, Ras-related protein with tumor suppressor potential. Cancer Res. 2005 Apr 15; 65(8):3117-25. PMID: 15833841.
      View in: PubMed
    290. Leaner VD, Donninger H, Ellis CA, Clark GJ, Birrer MJ. p75-Ras-GRF1 is a c-Jun/AP-1 target protein: its up regulation results in increased Ras activity and is necessary for c-Jun-induced nonadherent growth of Rat1a cells. Mol Cell Biol. 2005 Apr; 25(8):3324-37. PMID: 15798216.
      View in: PubMed
    291. Katabami M, Donninger H, Hommura F, Leaner VD, Kinoshita I, Chick JF, Birrer MJ. Cyclin A is a c-Jun target gene and is necessary for c-Jun-induced anchorage-independent growth in RAT1a cells. J Biol Chem. 2005 Apr 29; 280(17):16728-38. PMID: 15737994.
      View in: PubMed
    292. Tsuda H, Birrer MJ, Ito YM, Ohashi Y, Lin M, Lee C, Wong WH, Rao PH, Lau CC, Berkowitz RS, Wong KK, Mok SC. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genet Cytogenet. 2004 Dec; 155(2):97-107. PMID: 15571795.
      View in: PubMed
    293. Donninger H, Bonome T, Radonovich M, Pise-Masison CA, Brady J, Shih JH, Barrett JC, Birrer MJ. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene. 2004 Oct 21; 23(49):8065-77. PMID: 15361855.
      View in: PubMed
    294. Elagib KE, Xiao M, Hussaini IM, Delehanty LL, Palmer LA, Racke FK, Birrer MJ, Ganapathy-Kanniappan S, Shanmugasundaram G, McDevitt MA, Goldfarb AN. Jun blockade of erythropoiesis: role for repression of GATA-1 by HERP2. Mol Cell Biol. 2004 Sep; 24(17):7779-94. PMID: 15314183.
      View in: PubMed
    295. Sherman ME, Berman J, Birrer MJ, Cho KR, Ellenson LH, Gorstein F, Seidman JD. Current challenges and opportunities for research on borderline ovarian tumors. Hum Pathol. 2004 Aug; 35(8):961-70. PMID: 15297963.
      View in: PubMed
    296. Kielosto M, Nummela P, Katainen R, Leaner V, Birrer MJ, H?ltt? E. Reversible regulation of the transformed phenotype of ornithine decarboxylase- and ras-overexpressing cells by dominant-negative mutants of c-Jun. Cancer Res. 2004 Jun 01; 64(11):3772-9. PMID: 15172983.
      View in: PubMed
    297. Hommura F, Katabami M, Leaner VD, Donninger H, Sumter TF, Resar LM, Birrer MJ. HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-Jun-induced anchorage-independent growth in Rat1a cells. Mol Cancer Res. 2004 May; 2(5):305-14. PMID: 15192124.
      View in: PubMed
    298. Zhou X, Jordan RC, Mok S, Birrer MJ, Wong DT. DNA copy number abnormality of oral squamous cell carcinoma detected with cDNA array-based comparative genomic hybridization. Cancer Genet Cytogenet. 2004 May; 151(1):90-2. PMID: 15120918.
      View in: PubMed
    299. Cuello M, Coats AO, Darko I, Ettenberg SA, Gardner GJ, Nau MM, Liu JR, Birrer MJ, Lipkowitz S. N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. Cell Death Differ. 2004 May; 11(5):527-41. PMID: 14765134.
      View in: PubMed
    300. Liu S, Brown CW, Berlin KD, Dhar A, Guruswamy S, Brown D, Gardner GJ, Birrer MJ, Benbrook DM. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem. 2004 Feb 12; 47(4):999-1007. PMID: 14761202.
      View in: PubMed
    301. Farley J, Uyehara C, Hashiro G, Belnap C, Birrer M, Salminen E. Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure. Gynecol Oncol. 2004 Feb; 92(2):596-602. PMID: 14766253.
      View in: PubMed
    302. Tsuda H, Bandera CA, Birrer MJ, Hashiguchi Y, Berkowitz RS, Mok SC. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology. 2004; 67(3-4):291-9. PMID: 15557791.
      View in: PubMed
    303. Farley JH, Birrer MJ. Biologic directed therapies in gynecologic oncology. Curr Oncol Rep. 2003 Nov; 5(6):459-67. PMID: 14521804.
      View in: PubMed
    304. Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res. 2003 Oct 15; 9(13):4811-8. PMID: 14581352.
      View in: PubMed
    305. Romashko J, Horowitz S, Franek WR, Palaia T, Miller EJ, Lin A, Birrer MJ, Scott W, Mantell LL. MAPK pathways mediate hyperoxia-induced oncotic cell death in lung epithelial cells. Free Radic Biol Med. 2003 Oct 15; 35(8):978-93. PMID: 14556862.
      View in: PubMed
    306. Winter WE, Seidman JD, Krivak TC, Chauhan S, Carlson JW, Rose GS, Birrer MJ. Clinicopathological analysis of c-kit expression in carcinosarcomas and leiomyosarcomas of the uterine corpus. Gynecol Oncol. 2003 Oct; 91(1):3-8. PMID: 14529656.
      View in: PubMed
    307. Trepel J, Birrer MJ. A link between histone deacetylase inhibitors and NF- kappaB signaling. Cell Cycle. 2003 Sep-Oct; 2(5):452-3. PMID: 12963841.
      View in: PubMed
    308. Leaner VD, Kinoshita I, Birrer MJ. AP-1 complexes containing cJun and JunB cause cellular transformation of Rat1a fibroblasts and share transcriptional targets. Oncogene. 2003 Aug 28; 22(36):5619-29. PMID: 12944910.
      View in: PubMed
    309. Shen YH, Godlewski J, Zhu J, Sathyanarayana P, Leaner V, Birrer MJ, Rana A, Tzivion G. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J Biol Chem. 2003 Jul 18; 278(29):26715-21. PMID: 12738796.
      View in: PubMed
    310. Kinoshita I, Leaner V, Katabami M, Manzano RG, Dent P, Sabichi A, Birrer MJ. Identification of cJun-responsive genes in Rat-1a cells using multiple techniques: increased expression of stathmin is necessary for cJun-mediated anchorage-independent growth. Oncogene. 2003 May 08; 22(18):2710-22. PMID: 12743595.
      View in: PubMed
    311. Farley J, Smith LM, Darcy KM, Sobel E, O'Connor D, Henderson B, Morrison LE, Birrer MJ. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. Cancer Res. 2003 Mar 15; 63(6):1235-41. PMID: 12649182.
      View in: PubMed
    312. Dent P, Qiao L, Gilfor D, Birrer M, Grant S, Fisher PB. The regulation of tumor suppressor genes by oncogenes. Methods Mol Biol. 2003; 222:269-92. PMID: 12710693.
      View in: PubMed
    313. Zeinoun Z, Teugels E, Vermeij J, Neyns B, Birrer M, De Gr?ve J. Restoration of an impaired TGF-beta1 autocrine growth-inhibitory circuit results in growth inhibition of ovarian epithelial cancer cells and complete inhibition of their tumorigenicity. Cancer Detect Prev. 2003; 27(5):380-8. PMID: 14585325.
      View in: PubMed
    314. Quong J, Eppenberger-Castori S, Moore D, Scott GK, Birrer MJ, Kueng W, Eppenberger U, Benz CC. Age-dependent changes in breast cancer hormone receptors and oxidant stress markers. Breast Cancer Res Treat. 2002 Dec; 76(3):221-36. PMID: 12462383.
      View in: PubMed
    315. Bowen C, Birrer M, Gelmann EP. Retinoblastoma protein-mediated apoptosis after gamma-irradiation. J Biol Chem. 2002 Nov 22; 277(47):44969-79. PMID: 12297496.
      View in: PubMed
    316. Manzano RG, Montuenga LM, Dayton M, Dent P, Kinoshita I, Vicent S, Gardner GJ, Nguyen P, Choi YH, Trepel J, Auersperg N, Birrer MJ. CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential. Oncogene. 2002 Jun 27; 21(28):4435-47. PMID: 12080474.
      View in: PubMed
    317. Birrer M, Do DD, Mahler F, Triller J, Baumgartner I. Treatment of renal artery fibromuscular dysplasia with balloon angioplasty: a prospective follow-up study. Eur J Vasc Endovasc Surg. 2002 Feb; 23(2):146-52. PMID: 11863332.
      View in: PubMed
    318. Gardner GJ, Birrer MJ. Ovarian tumors of low malignant potential: Can molecular biology solve this enigma? J Natl Cancer Inst. 2001 Aug 01; 93(15):1122-3. PMID: 11481376.
      View in: PubMed
    319. Birrer M. [Macroangiopathy in diabetes mellitus]. Vasa. 2001 Jul; 30(3):168-74. PMID: 11582946.
      View in: PubMed
    320. Krivak TC, McBroom JW, Seidman J, Venzon D, Crothers B, MacKoul PJ, Rose GS, Carlson JW, Birrer MJ. Abnormal fragile histidine triad (FHIT) expression in advanced cervical carcinoma: a poor prognostic factor. Cancer Res. 2001 Jun 01; 61(11):4382-5. PMID: 11389064.
      View in: PubMed
    321. Birrer M, Mahler F, Baumgartner I, Triller J, Do DD. Parallel stent placement for maldeployed iliac stent. Eur J Vasc Endovasc Surg. 2001 Jun; 21(6):572-4. PMID: 11397036.
      View in: PubMed
    322. Fan M, Goodwin ME, Birrer MJ, Chambers TC. The c-Jun NH(2)-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res. 2001 Jun 01; 61(11):4450-8. PMID: 11389075.
      View in: PubMed
    323. Ebina M, Mart?nez A, Birrer MJ, Ilona Linnoila R. In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers. Oncogene. 2001 May 03; 20(20):2579-86. PMID: 11420668.
      View in: PubMed
    324. Nycum LR, Smith LM, Farley JH, Kost ER, Method MW, Birrer MJ. The role of p27 in endometrial carcinoma. Gynecol Oncol. 2001 May; 81(2):242-6. PMID: 11330957.
      View in: PubMed
    325. Kim JS, Pirnia F, Choi YH, Nguyen PM, Knepper B, Tsokos M, Schulte TW, Birrer MJ, Blagosklonny MV, Schaefer O, Mushinski JF, Trepel JB. Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint. Oncogene. 2000 Dec 07; 19(52):6082-90. PMID: 11146561.
      View in: PubMed
    326. Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem. 2000 Nov 17; 275(46):35669-72. PMID: 10998413.
      View in: PubMed
    327. Paasinen-Sohns A, Kielosto M, K??ri?inen E, Eloranta T, Laine A, J?nne OA, Birrer MJ, H?ltt? E. c-Jun activation-dependent tumorigenic transformation induced paradoxically by overexpression or block of S-adenosylmethionine decarboxylase. J Cell Biol. 2000 Nov 13; 151(4):801-10. PMID: 11076965.
      View in: PubMed
    328. Rinehart-Kim J, Johnston M, Birrer M, Bos T. Alterations in the gene expression profile of MCF-7 breast tumor cells in response to c-Jun. Int J Cancer. 2000 Oct 15; 88(2):180-90. PMID: 11004666.
      View in: PubMed
    329. Korsakas S, Chatterjee T, Reber PU, Bockisch G, Birrer M. [Giant, isolated aneurysms of the common iliac artery]. Schweiz Med Wochenschr. 2000 Oct 14; 130(41):1501. PMID: 11075415.
      View in: PubMed
    330. Farley JH, Nycum LR, Birrer MJ, Park RC, Taylor RR. Age-specific survival of women with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2000 Oct; 79(1):86-9. PMID: 11006037.
      View in: PubMed
    331. Farley J, Gray K, Nycum L, Prentice M, Birrer MJ, Jakowlew SB. Endocervical cancer is associated with an increase in the ligands and receptors for transforming growth factor-beta and a contrasting decrease in p27(Kip1). Gynecol Oncol. 2000 Aug; 78(2):113-22. PMID: 10926789.
      View in: PubMed
    332. Baumgartner I, von Aesch K, Do DD, Triller J, Birrer M, Mahler F. Stent placement in ostial and nonostial atherosclerotic renal arterial stenoses: a prospective follow-up study. Radiology. 2000 Aug; 216(2):498-505. PMID: 10924577.
      View in: PubMed
    333. Zehnder T, Birrer M, Do DD, Baumgartner I, Triller J, Nachbur B, Mahler F. Percutaneous catheter thrombus aspiration for acute or subacute arterial occlusion of the legs: how much thrombolysis is needed? Eur J Vasc Endovasc Surg. 2000 Jul; 20(1):41-6. PMID: 10906296.
      View in: PubMed
    334. Schmitz MJ, Hendricks DT, Farley J, Taylor RR, Geradts J, Rose GS, Birrer MJ. p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma. Gynecol Oncol. 2000 Jun; 77(3):439-45. PMID: 10831356.
      View in: PubMed
    335. Liu H, Sidiropoulos P, Song G, Pagliari LJ, Birrer MJ, Stein B, Anrather J, Pope RM. TNF-alpha gene expression in macrophages: regulation by NF-kappa B is independent of c-Jun or C/EBP beta. J Immunol. 2000 Apr 15; 164(8):4277-85. PMID: 10754326.
      View in: PubMed
    336. Cartee L, Vrana JA, Wang Z, Park JS, Birrer M, Fisher PB, Grant S, Dent P. Inhibition of the mitogen activated protein kinase pathway potentiates radiation-induced cell killing via cell cycle arrest at the G2/M transition and independently of increased signaling by the JNK/c-Jun pathway. Int J Oncol. 2000 Feb; 16(2):413-22. PMID: 10639586.
      View in: PubMed
    337. Park JS, Boyer S, Mitchell K, Gilfor D, Birrer M, Darlington G, El Deiry W, Firestone GL, Munger K, Band V, Fisher PB, Dent P. Expression of human papilloma virus E7 protein causes apoptosis and inhibits DNA synthesis in primary hepatocytes via increased expression of p21(Cip-1/WAF1/MDA6). J Biol Chem. 2000 Jan 07; 275(1):18-28. PMID: 10617580.
      View in: PubMed
    338. Johnson AC, Murphy BA, Matelis CM, Rubinstein Y, Piebenga EC, Akers LM, Neta G, Vinson C, Birrer M. Activator protein-1 mediates induced but not basal epidermal growth factor receptor gene expression. Mol Med. 2000 Jan; 6(1):17-27. PMID: 10803405.
      View in: PubMed
    339. Smith LM, Wise SC, Hendricks DT, Sabichi AL, Bos T, Reddy P, Brown PH, Birrer MJ. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype. Oncogene. 1999 Oct 28; 18(44):6063-70. PMID: 10557095.
      View in: PubMed
    340. Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ, Geradts J. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res. 1999 Oct 15; 59(20):5270-4. PMID: 10537308.
      View in: PubMed
    341. Wang N, Verna L, Hardy S, Zhu Y, Ma KS, Birrer MJ, Stemerman MB. c-Jun triggers apoptosis in human vascular endothelial cells. Circ Res. 1999 Sep 03; 85(5):387-93. PMID: 10473668.
      View in: PubMed
    342. Geradts J, Maynard R, Birrer MJ, Hendricks D, Abbondanzo SL, Fong KM, Barrett JC, Lombardi DP. Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohistochemical study of archival tissues. Am J Pathol. 1999 Jun; 154(6):1665-71. PMID: 10362791.
      View in: PubMed
    343. Rao GN, Katki KA, Madamanchi NR, Wu Y, Birrer MJ. JunB forms the majority of the AP-1 complex and is a target for redox regulation by receptor tyrosine kinase and G protein-coupled receptor agonists in smooth muscle cells. J Biol Chem. 1999 Feb 26; 274(9):6003-10. PMID: 10026227.
      View in: PubMed
    344. Dent P, Jarvis WD, Birrer MJ, Fisher PB, Schmidt-Ullrich RK, Grant S. The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway; a potential route to radio- and chemo-sensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Leukemia. 1998 Dec; 12(12):1843-50. PMID: 9844914.
      View in: PubMed
    345. Yu W, Simmons-Menchaca M, You H, Brown P, Birrer MJ, Sanders BG, Kline K. RRR-alpha-tocopheryl succinate induction of prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells. Mol Carcinog. 1998 Aug; 22(4):247-57. PMID: 9726817.
      View in: PubMed
    346. Jacobs-Helber SM, Wickrema A, Birrer MJ, Sawyer ST. AP1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cells. Mol Cell Biol. 1998 Jul; 18(7):3699-707. PMID: 9632752.
      View in: PubMed
    347. Carter S, Auer KL, Reardon DB, Birrer M, Fisher PB, Valerie K, Schmidt-Ullrich R, Mikkelsen R, Dent P. Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene. 1998 May 28; 16(21):2787-96. PMID: 9652746.
      View in: PubMed
    348. Zagariya A, Mungre S, Lovis R, Birrer M, Ness S, Thimmapaya B, Pope R. Tumor necrosis factor alpha gene regulation: enhancement of C/EBPbeta-induced activation by c-Jun. Mol Cell Biol. 1998 May; 18(5):2815-24. PMID: 9566900.
      View in: PubMed
    349. Wise SC, Burmeister LA, Zhou XF, Bubulya A, Oberfield JL, Birrer MJ, Shemshedini L. Identification of domains of c-Jun mediating androgen receptor transactivation. Oncogene. 1998 Apr 16; 16(15):2001-9. PMID: 9591784.
      View in: PubMed
    350. Sabichi AL, Hendricks DT, Bober MA, Birrer MJ. Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst. 1998 Apr 15; 90(8):597-605. PMID: 9554442.
      View in: PubMed
    351. Leyton J, Coelho T, Coy DH, Jakowlew S, Birrer MJ, Moody TW. PACAP(6-38) inhibits the growth of prostate cancer cells. Cancer Lett. 1998 Mar 13; 125(1-2):131-9. PMID: 9566707.
      View in: PubMed
    352. Auer KL, Contessa J, Brenz-Verca S, Pirola L, Rusconi S, Cooper G, Abo A, Wymann MP, Davis RJ, Birrer M, Dent P. The Ras/Rac1/Cdc42/SEK/JNK/c-Jun cascade is a key pathway by which agonists stimulate DNA synthesis in primary cultures of rat hepatocytes. Mol Biol Cell. 1998 Mar; 9(3):561-73. PMID: 9487126.
      View in: PubMed
    353. Szabo E, Francis J, Birrer MJ. Alterations in differentiation and apoptosis induced by bufalin in cJun overexpressing U-937 cells. Int J Oncol. 1998 Feb; 12(2):403-9. PMID: 9458368.
      View in: PubMed
    354. Jarvis WD, Fornari FA, Auer KL, Freemerman AJ, Szabo E, Birrer MJ, Johnson CR, Barbour SE, Dent P, Grant S. Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. Mol Pharmacol. 1997 Dec; 52(6):935-47. PMID: 9415703.
      View in: PubMed
    355. Smith LM, Birrer MJ, Stampfer MR, Brown PH. Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells. Cancer Res. 1997 Jul 15; 57(14):3046-54. PMID: 9230221.
      View in: PubMed
    356. Zhao B, Yu W, Qian M, Simmons-Menchaca M, Brown P, Birrer MJ, Sanders BG, Kline K. Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells. Mol Carcinog. 1997 Jul; 19(3):180-90. PMID: 9254885.
      View in: PubMed
    357. Hendricks DT, Taylor R, Reed M, Birrer MJ. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res. 1997 Jun 01; 57(11):2112-5. PMID: 9187105.
      View in: PubMed
    358. Potapova O, Haghighi A, Bost F, Liu C, Birrer MJ, Gjerset R, Mercola D. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J Biol Chem. 1997 May 30; 272(22):14041-4. PMID: 9162025.
      View in: PubMed
    359. Hall KL, Teneriello MG, Taylor RR, Lemon S, Ebina M, Linnoila RI, Norris JH, Park RC, Birrer MJ. Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas. Gynecol Oncol. 1997 May; 65(2):330-5. PMID: 9159347.
      View in: PubMed
    360. Birrer MJ. Discoveries in the cell cycle and ovarian cancer. Gynecol Oncol. 1997 Feb; 64(2):187-8. PMID: 9038262.
      View in: PubMed
    361. Parker MF, Arroyo GF, Geradts J, Sabichi AL, Park RC, Taylor RR, Birrer MJ. Molecular characterization of adenocarcinoma of the cervix. Gynecol Oncol. 1997 Feb; 64(2):242-51. PMID: 9038270.
      View in: PubMed
    362. Pisegna JR, Leyton J, Coelho T, Hida T, Jakowlew S, Birrer M, Fridkin M, Gozes I, Moody TW. PACAP hybrid: a new PACAP receptor antagonist. Life Sci. 1997; 61(6):631-9. PMID: 9250719.
      View in: PubMed
    363. Smith LM, Birrer MJ. Use of transcription factors as agents and targets for drug development. Oncology (Williston Park). 1996 Oct; 10(10):1532-8; discussion 1541-2. PMID: 8905845.
      View in: PubMed
    364. Brown PH, Kim SH, Wise SC, Sabichi AL, Birrer MJ. Dominant-negative mutants of cJun inhibit AP-1 activity through multiple mechanisms and with different potencies. Cell Growth Differ. 1996 Aug; 7(8):1013-21. PMID: 8853897.
      View in: PubMed
    365. Zia H, Hida T, Jakowlew S, Birrer M, Gozes Y, Reubi JC, Fridkin M, Gozes I, Moody TW. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res. 1996 Aug 01; 56(15):3486-9. PMID: 8758916.
      View in: PubMed
    366. Freemerman AJ, Turner AJ, Birrer MJ, Szabo E, Valerie K, Grant S. Role of c-jun in human myeloid leukemia cell apoptosis induced by pharmacological inhibitors of protein kinase C. Mol Pharmacol. 1996 May; 49(5):788-95. PMID: 8622627.
      View in: PubMed
    367. Grant S, Freemerman AJ, Birrer MJ, Martin HA, Turner AJ, Szabo E, Chelliah J, Jarvis WD. Effect of 1-beta-D-arabinofuranosylcytosine on apoptosis and differentiation in human monocytic leukemia cells (U937) expressing a c-Jun dominant-negative mutant protein (TAM67). Cell Growth Differ. 1996 May; 7(5):603-13. PMID: 8732670.
      View in: PubMed
    368. Antinore MJ, Birrer MJ, Patel D, Nader L, McCance DJ. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO J. 1996 Apr 15; 15(8):1950-60. PMID: 8617242.
      View in: PubMed
    369. Verheij M, Bose R, Lin XH, Yao B, Jarvis WD, Grant S, Birrer MJ, Szabo E, Zon LI, Kyriakis JM, Haimovitz-Friedman A, Fuks Z, Kolesnick RN. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature. 1996 Mar 07; 380(6569):75-9. PMID: 8598911.
      View in: PubMed
    370. Kim S, Brown PH, Birrer MJ. The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor. Oncogene. 1996 Mar 07; 12(5):1043-53. PMID: 8649795.
      View in: PubMed
    371. Chen TK, Smith LM, Gebhardt DK, Birrer MJ, Brown PH. Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol Carcinog. 1996 Mar; 15(3):215-26. PMID: 8597534.
      View in: PubMed
    372. Szabo E, Riffe ME, Steinberg SM, Birrer MJ, Linnoila RI. Altered cJUN expression: an early event in human lung carcinogenesis. Cancer Res. 1996 Jan 15; 56(2):305-15. PMID: 8542585.
      View in: PubMed
    373. Draoui M, Hida T, Jakowlew S, Birrer M, Zia F, Moody TW. PACAP stimulates c-fos mRNAs in small cell lung cancer cells. Life Sci. 1996; 59(4):307-13. PMID: 8761002.
      View in: PubMed
    374. Sabichi AL, Birrer MJ. Regulation of nuclear oncogenes expressed in lung cancer cell lines. J Cell Biochem Suppl. 1996; 24:218-27. PMID: 8806104.
      View in: PubMed
    375. Lengye E, Singh B, Gum R, Nerlov C, Sabichi A, Birrer M, Boyd D. Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. Oncogene. 1995 Dec 21; 11(12):2639-48. PMID: 8545121.
      View in: PubMed
    376. Taylor RR, Linnoila RI, Gerardts J, Teneriello MG, Nash JD, Park RC, Birrer MJ. Abnormal expression of the retinoblastoma gene in ovarian neoplasms and correlation to p53 and K-ras mutations. Gynecol Oncol. 1995 Sep; 58(3):307-11. PMID: 7545631.
      View in: PubMed
    377. Birrer MJ. Translational research and epithelial carcinogenesis: molecular diagnostic assays now--molecular screening assays soon? J Natl Cancer Inst. 1995 Jul 19; 87(14):1041-3. PMID: 7616591.
      View in: PubMed
    378. Cippitelli M, Sica A, Viggiano V, Ye J, Ghosh P, Birrer MJ, Young HA. Negative transcriptional regulation of the interferon-gamma promoter by glucocorticoids and dominant negative mutants of c-Jun. J Biol Chem. 1995 May 26; 270(21):12548-56. PMID: 7759501.
      View in: PubMed
    379. Watts RG, Ben-Ari ET, Bernstein LR, Birrer MJ, Winterstein D, Wendel E, Colburn NH. c-jun and multistage carcinogenesis: association of overexpression of introduced c-jun with progression toward a neoplastic endpoint in mouse JB6 cells sensitive to tumor promoter-induced transformation. Mol Carcinog. 1995 May; 13(1):27-36. PMID: 7766308.
      View in: PubMed
    380. Draoui M, Chung P, Park M, Birrer M, Jakowlew S, Moody TW. Bombesin stimulates c-fos and c-jun mRNAs in small cell lung cancer cells. Peptides. 1995; 16(2):289-92. PMID: 7784258.
      View in: PubMed
    381. Rapp UR, Troppmair J, Beck T, Birrer MJ. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant. Oncogene. 1994 Dec; 9(12):3493-8. PMID: 7970709.
      View in: PubMed
    382. Taylor RR, Teneriello MG, Nash JD, Park RC, Birrer MJ. The molecular genetics of gyn malignancies. Oncology (Williston Park). 1994 Oct; 8(10):63-70, 73; discussion 73, 78-82. PMID: 7803216.
      View in: PubMed
    383. Petrak D, Memon SA, Birrer MJ, Ashwell JD, Zacharchuk CM. Dominant negative mutant of c-Jun inhibits NF-AT transcriptional activity and prevents IL-2 gene transcription. J Immunol. 1994 Sep 01; 153(5):2046-51. PMID: 8051409.
      View in: PubMed
    384. Szabo E, Preis LH, Birrer MJ. Constitutive cJun expression induces partial macrophage differentiation in U-937 cells. Cell Growth Differ. 1994 Apr; 5(4):439-46. PMID: 8043518.
      View in: PubMed
    385. Brown PH, Chen TK, Birrer MJ. Mechanism of action of a dominant-negative mutant of c-Jun. Oncogene. 1994 Mar; 9(3):791-9. PMID: 8108121.
      View in: PubMed
    386. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A. 1994 Jan 18; 91(2):609-13. PMID: 8290571.
      View in: PubMed
    387. Domann FE, Levy JP, Birrer MJ, Bowden GT. Stable expression of a c-JUN deletion mutant in two malignant mouse epidermal cell lines blocks tumor formation in nude mice. Cell Growth Differ. 1994 Jan; 5(1):9-16. PMID: 8123597.
      View in: PubMed
    388. Kurie JM, Brown P, Salk E, Scheinberg D, Birrer M, Deutsch P, Dmitrovsky E. Cooperation between retinoic acid and phorbol esters enhances human teratocarcinoma differentiation. Differentiation. 1993 Sep; 54(2):115-22. PMID: 8243888.
      View in: PubMed
    389. Szabo E, Birrer MJ, Mulshine JL. Early detection of lung cancer. Semin Oncol. 1993 Aug; 20(4):374-82. PMID: 8342067.
      View in: PubMed
    390. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC, Birrer MJ. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res. 1993 Jul 01; 53(13):3103-8. PMID: 8319218.
      View in: PubMed
    391. Sabichi AL, Birrer MJ. The molecular biology of lung cancer: application to early detection and prevention. Oncology (Williston Park). 1993 Jun; 7(6):19-26; discussion 31-2, 37. PMID: 8318356.
      View in: PubMed
    392. Brown PH, Alani R, Preis LH, Szabo E, Birrer MJ. Suppression of oncogene-induced transformation by a deletion mutant of c-jun. Oncogene. 1993 Apr; 8(4):877-86. PMID: 8455942.
      View in: PubMed
    393. Mulshine JL, Treston AM, Brown PH, Birrer MJ, Shaw GL. Initiators and promoters of lung cancer. Chest. 1993 Jan; 103(1 Suppl):4S-11S. PMID: 8380133.
      View in: PubMed
    394. Barrett J, Birrer MJ, Kato GJ, Dosaka-Akita H, Dang CV. Activation domains of L-Myc and c-Myc determine their transforming potencies in rat embryo cells. Mol Cell Biol. 1992 Jul; 12(7):3130-7. PMID: 1620120.
      View in: PubMed
    395. Birrer MJ, Brown PH. Application of molecular genetics to the early diagnosis and screening of lung cancer. Cancer Res. 1992 May 01; 52(9 Suppl):2658s-2664s. PMID: 1562996.
      View in: PubMed
    396. Bar-Ner M, Messing LT, Cultraro CM, Birrer MJ, Segal S. Regions within the c-Myc protein that are necessary for transformation are also required for inhibition of differentiation of murine erythroleukemia cells. Cell Growth Differ. 1992 Mar; 3(3):183-90. PMID: 1633109.
      View in: PubMed
    397. Mulshine JL, Linnoila RI, Treston AM, Scott FM, Quinn K, Avis I, Shaw GL, Jensen SM, Brown P, Birrer MJ, et al. Candidate biomarkers for application as intermediate end points of lung carcinogenesis. J Cell Biochem Suppl. 1992; 16G:183-6. PMID: 1469899.
      View in: PubMed
    398. Mulshine JL, Linnoila RI, Jensen SM, Magnani JL, Tockman MS, Gupta PK, Scott FS, Avis I, Quinn K, Birrer MJ, et al. Rational targets for the early detection of lung cancer. J Natl Cancer Inst Monogr. 1992; (13):183-90. PMID: 1389692.
      View in: PubMed
    399. Birrer MJ, Alani R, Cuttitta F, Preis LH, Sabich AL, Sanders DA, Siegfried JM, Szabo E, Brown PH. Early events in the neoplastic transformation of respiratory epithelium. J Natl Cancer Inst Monogr. 1992; (13):31-7. PMID: 1389694.
      View in: PubMed
    400. Mulshine JL, Birrer M, Treston AM, Scott F, Quinn K, Avis I, Cuttitta F. Growth factors and other targets for rational application as intervention agents. Adv Exp Med Biol. 1992; 320:81-8. PMID: 1442286.
      View in: PubMed
    401. Smeal T, Binetruy B, Mercola DA, Birrer M, Karin M. Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73. Nature. 1991 Dec 12; 354(6353):494-6. PMID: 1749429.
      View in: PubMed
    402. Alani R, Brown P, Bin?truy B, Dosaka H, Rosenberg RK, Angel P, Karin M, Birrer MJ. The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells. Mol Cell Biol. 1991 Dec; 11(12):6286-95. PMID: 1944289.
      View in: PubMed
    403. Szabo E, Preis LH, Brown PH, Birrer MJ. The role of jun and fos gene family members in 12-O-tetradecanoylphorbol-13-acetate induced hemopoietic differentiation. Cell Growth Differ. 1991 Oct; 2(10):475-82. PMID: 1751404.
      View in: PubMed
    404. Kim JH, Takahashi T, Chiba I, Park JG, Birrer MJ, Roh JK, De Lee H, Kim JP, Minna JD, Gazdar AF. Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. J Natl Cancer Inst. 1991 Jul 03; 83(13):938-43. PMID: 1676761.
      View in: PubMed
    405. Dosaka-Akita H, Rosenberg RK, Minna JD, Birrer MJ. A complex pattern of translational initiation and phosphorylation in L-myc proteins. Oncogene. 1991 Mar; 6(3):371-8. PMID: 1849244.
      View in: PubMed
    406. Bliss DP, Battey JF, Linnoila RI, Birrer MJ, Gazdar AF, Johnson BE. Expression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines. J Natl Cancer Inst. 1990 Feb 21; 82(4):305-10. PMID: 2153841.
      View in: PubMed
    407. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989 Oct 27; 246(4929):491-4. PMID: 2554494.
      View in: PubMed
    408. Birrer MJ, Raveh L, Dosaka H, Segal S. A transfected L-myc gene can substitute for c-myc in blocking murine erythroleukemia differentiation. Mol Cell Biol. 1989 Jun; 9(6):2734-7. PMID: 2668739.
      View in: PubMed
    409. Sch?tte J, Minna JD, Birrer MJ. Deregulated expression of human c-jun transforms primary rat embryo cells in cooperation with an activated c-Ha-ras gene and transforms rat-1a cells as a single gene. Proc Natl Acad Sci U S A. 1989 Apr; 86(7):2257-61. PMID: 2648396.
      View in: PubMed
    410. Minna JD, Sch?tte J, Viallet J, Thomas F, Kaye FJ, Takahashi T, Nau M, Whang-Peng J, Birrer M, Gazdar AF. Transcription factors and recessive oncogenes in the pathogenesis of human lung cancer. Int J Cancer Suppl. 1989; 4:32-4. PMID: 2530182.
      View in: PubMed
    411. Birrer MJ, Minna JD. Genetic changes in the pathogenesis of lung cancer. Annu Rev Med. 1989; 40:305-17. PMID: 2658754.
      View in: PubMed
    412. De Greve J, Battey J, Fedorko J, Birrer M, Evan G, Kaye F, Sausville E, Minna J. The human L-myc gene encodes multiple nuclear phosphoproteins from alternatively processed mRNAs. Mol Cell Biol. 1988 Oct; 8(10):4381-8. PMID: 3054516.
      View in: PubMed
    413. Krystal G, Birrer M, Way J, Nau M, Sausville E, Thompson C, Minna J, Battey J. Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer. Mol Cell Biol. 1988 Aug; 8(8):3373-81. PMID: 2850489.
      View in: PubMed
    414. Birrer MJ, Segal S, DeGreve JS, Kaye F, Sausville EA, Minna JD. L-myc cooperates with ras to transform primary rat embryo fibroblasts. Mol Cell Biol. 1988 Jun; 8(6):2668-73. PMID: 2457153.
      View in: PubMed
    415. Birrer MJ, Minna JD. Molecular genetics of lung cancer. Semin Oncol. 1988 Jun; 15(3):226-35. PMID: 3289123.
      View in: PubMed
    416. Kaye F, Battey J, Nau M, Brooks B, Seifter E, De Greve J, Birrer M, Sausville E, Minna J. Structure and expression of the human L-myc gene reveal a complex pattern of alternative mRNA processing. Mol Cell Biol. 1988 Jan; 8(1):186-95. PMID: 2827002.
      View in: PubMed
    417. Birrer MJ, Young RC. Differential diagnosis of jaundice in lymphoma patients. Semin Liver Dis. 1987 Aug; 7(3):269-77. PMID: 3317863.
      View in: PubMed
    418. Minna JD, Battey JF, Birrer M, Brooks BJ, Cuttitta F, DeGreve J, Gazdar AF, Johnson BE, Nau MM, Sausville EA, et al. Chromosomal deletion, gene amplification, alternative processing, and autocrine growth factor production in the pathogenesis of human lung cancer. Princess Takamatsu Symp. 1986; 17:109-22. PMID: 3332004.
      View in: PubMed
    419. Birrer MJ, Udem S, Nathenson S, Bloom BR. Antigenic variants of measles virus. Nature. 1981 Sep 03; 293(5827):67-9. PMID: 6167866.
      View in: PubMed
    420. Birrer MJ, Bloom BR, Udem S. Characterization of measles polypeptides by monoclonal antibodies. Virology. 1981 Jan 30; 108(2):381-90. PMID: 7008338.
      View in: PubMed
    421. Ju G, Birrer M, Udem S, Bloom BR. Complementation analysis of measles virus mutants isolated from persistently infected lymphoblastoid cell lines. J Virol. 1980 Mar; 33(3):1004-12. PMID: 7365873.
      View in: PubMed
    Birrer's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (1155) concept(s)
    _
    Co-Authors Expand Description
    See all (5) people
    _
    Similar People Expand Description
    See all (37) people
    _
    Same Department Expand Description
    Search Department